

PRODUCT MONOGRAPH

PrNORVIR[®]

ritonavir oral solution - 80 mg/mL

PrNORVIR[®] SEC

ritonavir soft elastic capsules - 100 mg

Human Immunodeficiency Virus (HIV) Protease Inhibitor

Abbott Laboratories, Limited
8401, Trans-Canada Highway
Saint-Laurent (QC) CANADA H4S 1Z1

Date of Preparation:
August 9, 1996

Date of Previous Revision:
January 28, 2008

Date of Revision:
June 5, 2008

Submission Control No: 120307

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....3

SUMMARY PRODUCT INFORMATION3

INDICATIONS AND CLINICAL USE.....3

CONTRAINDICATIONS4

WARNINGS AND PRECAUTIONS.....5

ADVERSE REACTIONS.....12

DRUG INTERACTIONS17

DOSAGE AND ADMINISTRATION.....27

OVERDOSAGE28

ACTION AND CLINICAL PHARMACOLOGY29

STORAGE AND STABILITY.....32

DOSAGE FORMS, COMPOSITION AND PACKAGING33

PART II: SCIENTIFIC INFORMATION35

PHARMACEUTICAL INFORMATION.....35

CLINICAL TRIALS.....35

DETAILED PHARMACOLOGY41

MICROBIOLOGY42

TOXICOLOGY42

REFERENCES51

PART III: CONSUMER INFORMATION.....53

PrNORVIR®
ritonavir oral solution

PrNORVIR® SEC
ritonavir soft elastic capsules

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	Oral Solution - 80 mg/mL Soft Elastic Capsules - 100 mg	Ethanol, water, polyoxyl 35 castor oil, propylene glycol, anhydrous citric acid to adjust pH, saccharin sodium, peppermint oil, creamy caramel flavoring, and FD&C Yellow No. 6. Butylated hydroxytoluene, ethanol, gelatin, black opacode ink (iron oxide), oleic acid, polyoxyl 35 castor oil, purified water, titanium dioxide, sorbitol and glycerin. <i>This is a complete listing of nonmedicinal ingredients.</i>

INDICATIONS AND CLINICAL USE

NORVIR® (ritonavir oral solution) and NORVIR® SEC (ritonavir soft elastic capsules) are indicated in combination with other antiretroviral agents for:

- the treatment of HIV infection when therapy is warranted.

For patients with advanced HIV disease, this indication is based on the results from a study that showed a reduction in both mortality and AIDS-defining clinical events for patients who received ritonavir. Median duration of follow-up in this study was 6 months. The clinical benefit from ritonavir therapy for longer periods of treatment is unknown.

For patients with less advanced disease, this indication is based on changes in surrogate markers in studies evaluating patients who received ritonavir alone or in combination with other antiretroviral agents (see **CLINICAL TRIALS**).

Geriatrics (> 65 years of age): Clinical studies of ritonavir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, appropriate caution should be exercised in the administration and monitoring of ritonavir in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Pediatrics (2 to 16 years of age): The safety and effectiveness of ritonavir in pediatric patients below the age of 2 years have not been established. Although the database in HIV-infected patients age 2 to 16 years is much smaller, the adverse event profile seen during a clinical trial and post-marketing experience was similar to that observed for adult patients.

CONTRAINDICATIONS

- NORVIR[®] (ritonavir oral solution) and NORVIR[®] SEC (ritonavir soft elastic capsules) are contraindicated in patients with known hypersensitivity to ritonavir or any of its ingredients. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section of the Product Monograph.
- Co-administration of ritonavir is contraindicated with the drugs listed in **Table 1** (see also **DRUG INTERACTIONS, Serious Drug Interactions Box**) because competition for primarily CYP3A by ritonavir could result in inhibition of the metabolism of these drugs and create the potential for serious and/or life-threatening reactions such as cardiac arrhythmias, prolonged or increased sedation, and respiratory depression.

Drug Class	Drugs Within Class that are Contraindicated with Ritonavir	Clinical Comment
Alpha ₁ -Adrenoreceptor Antagonist	alfuzosin	CONTRAINDICATED due to potential for serious reactions such as hypotension (see DRUG INTERACTIONS, Drug-Drug Interactions, Effect of Ritonavir on Co-Administered Drugs).
Antiarrhythmics	amiodarone, bepridil, flecainide, propafenone, quinidine	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Antifungal	voriconazole	CONTRAINDICATED due to a significant reduction in voriconazole plasma concentrations and possible loss of effect (see DRUG INTERACTIONS, Effect of Ritonavir on Co-Administered Drugs).
Antihistamines	astemizole*, terfenadine*	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Ergot Derivatives	dihydroergotamine, ergonovine, ergotamine, methylergonovine	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by vasospasm and tissue ischemia.

Table 1 Drugs that are Contraindicated with Ritonavir		
Drug Class	Drugs Within Class that are Contraindicated with Ritonavir	Clinical Comment
GI Motility Agent	cisapride*	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Herbal Products	St. John's wort (<i>Hypericum perforatum</i>)	SHOULD NOT BE CO-ADMINISTERED WITH RITONAVIR: May lead to loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors.
HMG-CoA Reductase Inhibitors	lovastatin, simvastatin	SHOULD NOT BE CO-ADMINISTERED WITH RITONAVIR: Potential for serious reactions such as risk of myopathy including rhabdomyolysis.
Neuroleptic	pimozide	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Sedative/hypnotics	midazolam, triazolam	CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.

* Product no longer marketed in Canada.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur. Patients who exhibit these signs or symptoms should be evaluated and ritonavir therapy should be discontinued if a diagnosis of pancreatitis is made (see **WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic**).

General

Co-administration of NORVIR[®] (ritonavir oral solution) or NORVIR[®] SEC (ritonavir soft elastic capsules) with certain nonsedating antihistamines, sedative hypnotics, or antiarrhythmics may result in potentially serious and/or life-threatening adverse events due to possible effects of ritonavir on the hepatic metabolism of certain drugs. See **CONTRAINDICATIONS** and **DRUG INTERACTIONS**.

Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) both *in vitro* and *in vivo*. Ritonavir also inhibits CYP2D6 *in vitro*, but to a lesser extent than CYP3A. Co-administration of ritonavir and drugs primarily metabolized by CYP3A or CYP2D6 may result in increased plasma concentrations of other drugs that could increase or prolong its therapeutic and adverse effects (see **CONTRAINDICATIONS, Table 1** and **DRUG INTERACTIONS, Table 4, Table 5** and **Table 6**).

The magnitude of the interactions and therapeutic consequences between ritonavir and the drugs listed in **DRUG INTERACTIONS, Table 7 Predicted Drug Interactions: Use with Caution** cannot be predicted with any certainty. When co-administering ritonavir with any agent listed in **Table 7**, special attention is warranted.

Cardiac and neurologic events have been reported with ritonavir when coadministered with disopyramide, mexiletine, nefazodone, fluoxetine and beta blockers. The possibility of drug interactions cannot be excluded.

There have been post-marketing reports of drug interactions, including increased itraconazole levels, when ritonavir and itraconazole were co-administered.

Antimycobacterial

Saquinavir/ritonavir should not be given together with rifampin, due to the risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the three drugs are given together.

Corticosteroids

A drug interaction study in healthy subjects has shown that ritonavir significantly increases plasma fluticasone propionate exposures, resulting in significantly decreased serum cortisol concentrations. Systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression have been reported during postmarketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate. Therefore, co-administration of fluticasone propionate and ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects (see **DRUG INTERACTIONS**).

Erectile Dysfunction Agents

Particular caution should be used when prescribing sildenafil or tadalafil in patients receiving ritonavir. Co-administration of ritonavir with these drugs is expected to substantially increase their concentrations and may result in increased associated adverse events, such as hypotension, syncope, visual changes, and prolonged erection. Vardenafil should not be administered with ritonavir. (See **DRUG INTERACTIONS, Table 6**).

HMG-CoA Reductase Inhibitors

Concomitant use of ritonavir with lovastatin and simvastatin is not recommended (see **CONTRAINDICATIONS**). Caution should be exercised if HIV protease inhibitors, including ritonavir, are used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (*e.g.*, atorvastatin). While rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir coadministration. The risk of myopathy including rhabdomyolysis may be increased when HIV protease inhibitors, including ritonavir, are used in combination with these drugs.

Allergic Reactions

Allergic reactions including urticaria, mild skin eruptions, bronchospasm, and angioedema have been reported. Rare cases of anaphylaxis and Stevens-Johnson syndrome have also been reported.

Organ Targets for Toxicity

Toxicological studies in laboratory animals identified various organs as targets for toxicity at drug exposures below or approaching those achieved in patients participating in clinical trials with ritonavir. Because no safety margin or a small safety margin has been demonstrated in long-term studies, these organs should be assessed periodically or if clinical signs and symptoms occur during therapy (see **TOXICOLOGY**).

Co-Administration with Tipranavir

Co-administration of tipranavir with 200 mg ritonavir has been associated with reports of clinical hepatitis and hepatic decompensation including some fatalities (see **DRUG INTERACTIONS**). Refer to the APTIVUS[®] (tipranavir) Product Monograph for more information.

Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C co-infection, as these patients have an increased risk of hepatotoxicity.

Carcinogenesis and Mutagenesis

For a brief discussion of pre-clinical animal data, see **TOXICOLOGY**, **Carcinogenicity** and **Mutagenicity**.

Diabetes Mellitus/Hyperglycemia

New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycemia have been reported during post-marketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases diabetic ketoacidosis has occurred. In those patients who discontinue protease inhibitor therapy, hyperglycemia

persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established.

Fat Redistribution/Accumulation

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Hematologic

There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in patients with Hemophilia Type A and Type B treated with protease inhibitors. In some patients, additional Factor VIII was given. In more than half of the reported cases, treatment with protease inhibitors was continued or re-introduced. There is no proven relationship between protease inhibitors and such bleeding, however, the frequency of bleeding episodes should be closely monitored in patients on ritonavir.

Hepatic/Biliary/Pancreatic

Impaired Hepatic Function

Ritonavir is principally metabolized by the liver. Pre-clinical studies have identified the liver as a toxicity target (see **TOXICOLOGY**). Therefore, appropriate tests should be performed at treatment initiation and at periodic intervals to assess hepatic function.

Caution should be exercised when administering ritonavir to patients with impaired hepatic function.

Hepatic Reactions

Hepatic transaminase elevations exceeding 5 times the upper limit of normal, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir alone or in combination with other antiretroviral drugs (see **ADVERSE REACTIONS, Table 3**). There may be an increased risk for transaminase elevations in patients with underlying hepatitis B or C. Therefore, caution should be exercised when administering ritonavir to patients with pre-existing liver disease, liver enzyme abnormalities, or hepatitis.

There have been post-marketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients taking multiple concomitant medications and/or with advanced AIDS.

Pancreatitis

Pancreatitis has been observed in patients receiving ritonavir therapy, including those who developed hypertriglyceridemia. In some cases fatalities have been observed. Patients with advanced HIV disease may be at increased risk of elevated triglycerides and pancreatitis.

Pancreatitis should be considered if clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in laboratory values (such as increased serum lipase or amylase values) suggestive of pancreatitis should occur. Patients who exhibit these signs or symptoms should be evaluated and ritonavir therapy should be discontinued if a diagnosis of pancreatitis is made.

Immune Reconstitution Syndrome

Immune reconstitution syndrome has been reported in HIV-infected patients treated with combination antiretroviral therapy, including ritonavir. During the initial phase of treatment, patients responding to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis carinii* pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.

Cardiovascular

PR Interval Prolongation

Ritonavir has been shown to cause asymptomatic prolongation of the PR interval in some patients. Reports of second or third degree atrioventricular block in patients with underlying structural heart disease and preexisting conduction system abnormalities or in patients receiving drugs known to prolong the PR interval (such as verapamil or atazanavir) have been reported in patients receiving ritonavir. Ritonavir should be used with caution in such patients. (See **ACTION AND CLINICAL PHARMACOLOGY; Pharmacodynamics**; Effects on the Electrocardiogram)

Lipid Disorders

Treatment with ritonavir therapy alone or in combination with saquinavir has resulted in substantial increases in the concentration of total triglycerides and cholesterol (see **ADVERSE REACTIONS, Abnormal Hematologic and Clinical Chemistry Findings**). Triglycerides and cholesterol testing should be performed prior to initiating ritonavir therapy and at periodic intervals during therapy. Lipid disorders should be managed as clinically appropriate.

Neurologic

CNS penetration of ritonavir has not been established.

Resistance/Cross-resistance

Resistance

HIV-1 isolates with reduced susceptibility to ritonavir have been selected *in vitro*. Genotypic analysis of these isolates showed mutations in the HIV protease gene at amino acid positions 84 (Ile to Val), 82 (Val to Phe), 71 (Ala to Val), and 46 (Met to Ile). Phenotypic (n=18) and genotypic (n=44) changes in HIV isolates from selected patients treated with ritonavir were monitored in Phase I/II trials over a period of 3 to 32 weeks. Mutations associated with the HIV viral protease in isolates obtained from 41 patients appeared to occur in a stepwise and ordered fashion; in sequence, these mutations were position 82 (Val to Ala/Phe), 54 (Ile to Val), 71 (Ala to Val/Thr), and 36 (Ile to Leu), followed by combinations of mutations at an additional 5 specific amino acid positions.

Of 18 patients for which both phenotypic and genotypic analysis were performed on free virus isolated from plasma, 12 showed reduced susceptibility to ritonavir *in vitro*. All 18 patients possessed one or more mutations in the viral protease gene. The 82 mutation appeared to be necessary but not sufficient to confer phenotypic resistance. Phenotypic resistance was defined as a ≥ 5 -fold decrease in viral sensitivity *in vitro* from baseline. The clinical relevance of phenotypic and genotypic changes associated with ritonavir therapy has not been established.

Cross-Resistance

Among protease inhibitors variable cross-resistance has been recognized. Serial HIV isolates obtained from six patients during ritonavir therapy showed a decrease in ritonavir susceptibility *in vitro* but did not demonstrate a concordant decrease in susceptibility to saquinavir *in vitro* when compared to matched baseline isolates. However, isolates from two of these patients demonstrated decreased susceptibility to indinavir *in vitro* (8-fold). Isolates from 5 patients were also tested for cross-resistance to amprenavir and nelfinavir; isolates from 2 patients had a decrease in susceptibility to nelfinavir (12- to 14-fold), and none to amprenavir. Cross-resistance between ritonavir and reverse transcriptase inhibitors is unlikely because of the different enzyme targets involved. One ZDV-resistant HIV isolate tested *in vitro* retained full susceptibility to ritonavir.

Special Populations

Pregnant Women: There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

In rat fertility studies, hepatic toxicity precluded drug exposures equal to those achieved with the proposed human therapeutic dose. No effects on fertility in rats were produced at drug exposures approximately 40% (male) and 60% (female) of that achieved with the proposed human therapeutic dose.

No treatment-related malformations were observed when ritonavir was administered to pregnant rats or rabbits. Developmental toxicity observed in rats (early resorptions, decreased fetal body weight and ossification delays and developmental variations) occurred at a maternally toxic dosage at an exposure equivalent to approximately 30% of that achieved with the proposed therapeutic dose. A slight increase in the incidence of cryptorchidism was also noted in rats at an exposure approximately 22% of that achieved with the proposed therapeutic dose.

Developmental toxicity observed in rabbits (resorptions, decreased litter size and decreased fetal weights) also occurred at a maternally toxic dosage equivalent to 1.8 times the proposed therapeutic dose based on a body surface area conversion factor.

Antiretroviral Pregnancy Registry

To monitor maternal-fetal outcomes of pregnant women exposed to ritonavir, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.

Nursing Women: The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV. It is not known whether ritonavir is secreted in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed **not to breast-feed if they are receiving NORVIR[®] or NORVIR[®] SEC.**

Pediatrics (2 to 16 years of age): The safety and effectiveness of ritonavir in pediatric patients below the age of 2 years have not been established. Although the database in HIV-infected patients age 2 to 16 years is much smaller, the adverse event profile seen during a clinical trial and post-marketing experience was similar to that observed for adult patients.

Geriatrics (> 65 years of age): Clinical studies of ritonavir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, appropriate caution should be exercised in the administration and monitoring of ritonavir in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Monitoring and Laboratory Tests

Ritonavir has been associated with elevations in cholesterol, triglycerides, SGOT (AST), SGPT (ALT), GGT, CK, and uric acid. Appropriate laboratory testing should be performed prior to initiating ritonavir therapy and at periodic intervals or if any clinical signs or symptoms occur during therapy. For comprehensive information concerning laboratory test alterations associated with other antiretroviral agents, physicians should refer to the complete product information for each of these drugs.

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The safety of NORVIR[®] (ritonavir) alone and in combination with nucleoside reverse transcriptase inhibitors was studied in 1270 adult patients. **Table 2** lists treatment-emergent adverse events (at least possibly related and of at least moderate intensity) that occurred in 2% or greater of adult patients receiving ritonavir alone or in combination with nucleoside reverse transcriptase inhibitors in Study 245 or Study 247 and in combination with saquinavir in Study 462. In that study, 141 protease inhibitor-naïve, HIV-infected patients with mean baseline CD₄ of 300 cells/μL were randomized to one of four regimens of ritonavir + saquinavir, including ritonavir 400 mg twice-daily + saquinavir 400 mg twice-daily. Overall, the most frequently reported clinical adverse events, other than asthenia, among patients receiving ritonavir were gastrointestinal and neurological disturbances including nausea, diarrhea, vomiting, anorexia, abdominal pain, taste perversion, and circumoral and peripheral paresthesias. Similar adverse event profiles were reported in adult patients receiving ritonavir in other trials.

Adverse Events	Study 245 Naïve Patients ²			Study 247 Advanced Patients ³		Study 462 PI-Naïve Patients ⁴
	NORVIR [®] + ZDV n = 116	NORVIR [®] n = 117	ZDV n = 119	NORVIR [®] n = 541	Placebo n = 545	NORVIR [®] + Saquinavir n=141
Body as a Whole						
Abdominal Pain	5.2	6.0	5.9	8.3	5.1	2.1
Asthenia	28.4	10.3	11.8	15.3	6.4	16.3
Fever	1.7	0.9	1.7	5.0	2.4	0.7
Headache	7.8	6.0	6.7	6.5	5.7	4.3
Malaise	5.2	1.7	3.4	0.7	0.2	2.8
Pain (unspecified)	0.9	1.7	0.8	2.2	1.8	4.3
Cardiovascular						
Syncope	0.9	1.7	0.8	0.6	0.0	2.1
Vasodilation	3.4	1.7	0.8	1.7	0.0	3.5
Digestive						
Anorexia	8.6	1.7	4.2	7.8	4.2	4.3
Constipation	3.4	0.0	0.8	0.2	0.4	1.4
Diarrhea	25.0	15.4	2.5	23.3	7.9	22.7
Dyspepsia	2.6	0.0	1.7	5.9	1.5	0.7
Fecal Incontinence	0.0	0.0	0.0	0.0	0.0	2.8
Flatulence	2.6	0.9	1.7	1.7	0.7	3.5

Table 2
Percentage of Patients with Treatment-Emergent Adverse Events¹ of Moderate or Severe Intensity Occurring in ³ 2% of Adult Patients Receiving NORVIR[®] (ritonavir)

Adverse Events	Study 245 Naive Patients ²			Study 247 Advanced Patients ³		Study 462 PI-Naïve Patients ⁴
	NORVIR [®] + ZDV n = 116	NORVIR [®] n = 117	ZDV n = 119	NORVIR [®] n = 541	Placebo n = 545	NORVIR [®] + Saquinavir n=141
Liver Function Tests Abnormal	2.6	1.7	1.7	3.3	0.9	5.0
Local Throat Irritation	0.9	1.7	0.8	2.8	0.4	1.4
Nausea	46.6	25.6	26.1	29.8	8.4	18.4
Vomiting	23.3	13.7	12.6	17.4	4.4	7.1
Metabolic and Nutritional Creatinine Phosphokinase (CK) Increase	4.3	3.4	3.4	0.9	0.2	N/A
Hyperlipidemia	2.6	1.7	0.0	5.7	0.2	3.5
Weight Loss	0.0	0.0	0.0	2.4	1.7	0.0
Musculoskeletal Arthralgia	0.0	0.0	0.0	1.7	0.7	2.1
Myalgia	1.7	1.7	0.8	2.4	1.1	2.1
Nervous Anxiety	0.9	0.0	0.8	1.7	0.9	2.1
Circumoral Paresthesia	5.2	3.4	0.0	6.7	0.4	6.4
Confusion	0.0	0.9	0.0	0.6	0.6	2.1
Depression	1.7	1.7	2.5	1.7	0.7	7.1
Dizziness	5.2	2.6	3.4	3.9	1.1	8.5
Insomnia	3.4	2.6	0.8	2.0	1.8	2.8
Paresthesia	5.2	2.6	0.0	3.0	0.4	2.1
Peripheral Paresthesia	0.0	6.0	0.8	5.0	1.1	5.7
Somnolence	2.6	2.6	0.0	2.4	0.2	0.0
Thinking Abnormal	2.6	0.0	0.8	0.9	0.4	0.7
Respiratory Pharyngitis	0.9	2.6	0.0	0.4	0.4	1.4
Skin and Appendages Rash	0.9	0.0	0.8	3.5	1.5	0.7
Sweating	3.4	2.6	1.7	1.7	1.1	2.8
Special Senses Taste Perversion	17.2	11.1	8.4	7.0	2.2	5.0
Urogenital Nocturia	0.0	0.0	0.0	0.2	0.0	2.8

1 Includes those adverse events at least possibly related to study drug or of unknown relationship and excludes concurrent HIV conditions.

2 The median duration of treatment for patients randomized to regimens containing ritonavir in Study 245 was 9.1 months

3 The median duration of treatment for patients randomized to regimens containing ritonavir in Study 247 was 9.4 months

4 The median duration of treatment for patients in Study 462 was 48 weeks.

N/A Not available

Less Common Clinical Trial Adverse Drug Reactions (< 2%)

Adverse events occurring in less than 2% of adult patients receiving ritonavir in all Phase II/Phase III studies and considered at least possibly related or of unknown relationship to

treatment and of at least moderate intensity are listed below by body system.

<u>Body as a Whole</u>	Abdomen enlarged, accidental injury, allergic reaction, back pain, cachexia, chest pain, chills, facial edema, facial pain, flu syndrome, hormone level altered, hypothermia, kidney pain, neck pain, neck rigidity, pelvic pain, photosensitivity reaction, and substernal chest pain.
<u>Cardiovascular System</u>	Cardiovascular disorder, cerebral ischemia, cerebral venous thrombosis, hemorrhage, hypertension, hypotension, migraine, myocardial infarct, palpitation, peripheral vascular disorder, phlebitis, postural hypotension, tachycardia, and vasospasm.
<u>Digestive System</u>	Abnormal stools, bloody diarrhea, cheilitis, cholangitis, cholestatic jaundice, colitis, dry mouth, dysphagia, eructation, esophageal ulcer, esophagitis, gastritis, gastroenteritis, gastrointestinal disorder, gastrointestinal hemorrhage, gingivitis, hepatic coma, hepatitis, hepatomegaly, hepatosplenomegaly, ileitis, ileus, liver damage, melena, mouth ulcer, oral moniliasis, pancreatitis, periodontal abscess, pseudomembranous colitis, rectal disorder, rectal hemorrhage, sialadenitis, stomatitis, tenesmus, thirst, tongue edema, and ulcerative colitis.
<u>Endocrine System</u>	Adrenal cortex insufficiency and diabetes mellitus.
<u>Hemic and Lymphatic System</u>	Acute myeloblastic leukemia, anemia, ecchymosis, leukopenia, lymphadenopathy, lymphocytosis, myeloproliferative disorder, and thrombocytopenia.
<u>Metabolic and Nutritional Disorders</u>	Albuminuria, alcohol intolerance, avitaminosis, BUN increased, dehydration, edema, enzymatic abnormality, glycosuria, gout, hypercholesteremia, peripheral edema, and xanthomatosis.
<u>Musculoskeletal System</u>	Arthritis, arthrosis, bone disorder, bone pain, extraocular palsy, joint disorder, leg cramps, muscle cramps, muscle weakness, myositis, and twitching.
<u>Nervous System</u>	Abnormal dreams, abnormal gait, agitation, amnesia, aphasia, ataxia, coma, convulsion, dementia, depersonalization, diplopia, emotional lability, euphoria, grand mal convulsion, hallucinations, hyperesthesia, hyperkinesia, hypesthesia, incoordination, libido decreased, manic reaction, nervousness, neuralgia, neuropathy, paralysis, peripheral neuropathic pain, peripheral neuropathy,

peripheral sensory neuropathy, personality disorder, sleep disorder, speech disorder, stupor, subdural hematoma, tremor, urinary retention, vertigo, and vestibular disorder.

Respiratory System

Asthma, bronchitis, dyspnea, epistaxis, hiccup, hypoventilation, increased cough, interstitial pneumonia, larynx edema, lung disorder, rhinitis, and sinusitis.

Skin and Appendages

Acne, contact dermatitis, dry skin, eczema, erythema multiforme, exfoliative dermatitis, folliculitis, fungal dermatitis, furunculosis, maculopapular rash, molluscum contagiosum, onychomycosis, pruritus, psoriasis, pustular rash, seborrhea, skin discoloration, skin disorder, skin hypertrophy, skin melanoma, urticaria, and vesiculobullous rash.

Special Senses

Abnormal electro-oculogram, abnormal electroretinogram, abnormal vision, amblyopia/blurred vision, blepharitis, conjunctivitis, ear pain, eye disorder, eye pain, hearing impairment, increased cerumen, iritis, parosmia, photophobia, taste loss, tinnitus, uveitis, visual field defect, and vitreous disorder.

Urogenital System

Acute kidney failure, breast pain, cystitis, dysuria, hematuria, impotence, kidney calculus, kidney failure, kidney function abnormal, kidney pain, menorrhagia, penis disorder, polyuria, pyelonephritis, urethritis, urinary frequency, urinary tract infection, and vaginitis.

Abnormal Hematologic and Clinical Chemistry Findings

Table 3 shows the percentage of adult patients who developed marked laboratory abnormalities.

Table 3 Percentage of Adult Patients, by Study and Treatment Group, with Chemistry and Hematology Abnormalities Occurring in ≥ 2% of Patients Receiving NORVIR®							
Variable	Limit	Study 245 Naive Patients			Study 247 Advanced Patients		Study 462 PI-Naïve Patients
		NORVIR® + ZDV	NORVIR®	ZDV	NORVIR®	Placebo	NORVIR® + Saquinavir
<u>CHEMISTRY</u>	<u>HIGH</u>						
Alkaline Phosphatase	> 550 IU/L	-	0.9	-	2.3	2.2	-
Cholesterol	> 6.22 mmol/L	30.7	44.8	9.3	36.5	8.0	65.2
CK	> 1000 IU/L	9.6	12.1	11.0	9.1	6.3	9.9
GGT	> 300 IU/L	1.8	5.2	1.7	19.6	11.3	9.2
Glucose	> 13.88 mmol/L	2.6	0.9	0.8	0.9	1.3	0.7
SGOT (AST)	> 180 IU/L	5.3	9.5	2.5	6.4	7.0	7.8
SGPT (ALT)	> 215 IU/L	5.3	7.8	3.4	8.5	4.4	9.2
Total Bilirubin	> 61.56 µmol/L	-	0.9	0.8	1.3	0.2	2.1

Variable	Limit	Study 245 Naive Patients			Study 247 Advanced Patients		Study 462 PI-Naive Patients
		NORVIR [®] + ZDV	NORVIR [®]	ZDV	NORVIR [®]	Placebo	NORVIR [®] + Saquinavir
Triglycerides	> 9.04 mmol/L	9.6	17.2	3.4	33.6	9.4	23.4
Triglycerides	> 16.95 mmol/L	1.8	2.6	-	12.6	0.4	11.3
Triglycerides Fasting	> 16.95 mmol/L	1.5	1.3	-	9.9	0.3	-
Uric Acid	> 713.76 μ mol/L	-	-	-	3.8	0.2	1.4
<u>CHEMISTRY</u>	<u>LOW</u>						
Potassium	< 3.0 mEq/L	-	1.7	-	3.0	2.0	2.1
<u>HEMATOLOGY</u>	<u>HIGH</u>						
Eosinophils	> 1.0 x 10 ⁹ /L	-	2.6	1.7	2.6	3.3	0.7
Neutrophils	> 20 x 10 ⁹ /L	-	-	-	2.3	1.3	-
<u>HEMATOLOGY</u>	<u>LOW</u>						
Hematocrit	< 30%	2.6	-	0.8	17.3	22.0	0.7
Hemoglobin	< 80 g/L	0.9	-	-	3.8	3.9	-
Neutrophils	\leq 0.5 x 10 ⁹ /L	-	-	-	6.0	8.3	-
RBC	< 3.0 x 10 ¹² /L	1.8	-	5.9	18.6	24.4	-
WBC	< 2.5 x 10 ⁹ /L	-	0.9	6.8	36.9	59.4	3.5

1 ULN = upper limit of the normal range.
- Indicates no events reported.

Post-Market Adverse Drug Reactions

The following adverse events have been reported during post-marketing use of ritonavir. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to ritonavir exposure.

Cardiovascular System

Myocardial infarction has been reported. Cardiac and neurologic events have been reported when ritonavir has been co-administered with disopyramide, mexiletine, nefazodone, fluoxetine, and beta blockers. The possibility of drug interaction cannot be excluded.

Endocrine System

Hyperglycemia has been reported in individuals with and without a known history of diabetes.

Cushing's syndrome and adrenal suppression have been reported when ritonavir has been co-administered with fluticasone propionate.

Hemic and Lymphatic System

There have been reports of increased bleeding in patients with hemophilia A or B (see **WARNINGS AND PRECAUTIONS**,

Hematologic).

Metabolism and Nutrition Disorders

Redistribution/accumulation of body fat has been reported (see **WARNINGS AND PRECAUTIONS**). Dehydration, usually associated with gastrointestinal symptoms, and sometimes resulting in hypotension, syncope, or renal insufficiency has been reported. Syncope, orthostatic hypotension and renal insufficiency have also been reported without known dehydration.

Co-administration of ritonavir with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.

Nervous System Disorders

There have been post-marketing reports of seizure. Cause and effect relationship has not been established.

Reproductive System and Breast Disorders

Menorrhagia has been reported.

DRUG INTERACTIONS

Serious Drug Interactions

- See **CONTRAINDICATIONS**
- **Co-administration** (saquinavir/rifampin/ritonavir): Saquinavir and ritonavir should not be given together with rifampin due to risk of severe hepatotoxicity (presenting as increased transaminases) if the three drugs are given together.
- **Co-administration** (tipranavir/ritonavir): Tipranavir co-administered with 200 mg of ritonavir has been associated with reports of clinical hepatitis and hepatic decompensation including some fatalities. Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C co-infection, as these patients have an increased risk of hepatotoxicity.

Overview

Agents which increase CYP3A activity (*e.g.*, phenobarbital, carbamazepine, dexamethasone, phenytoin, rifampin, and rifabutin) would be expected to increase the clearance of ritonavir resulting in decreased ritonavir plasma concentrations. Tobacco use is associated with an 18%

decrease in the AUC of ritonavir.

Ritonavir can produce large increases in plasma concentrations of certain highly metabolized drugs. Ritonavir has a high affinity for several cytochrome P450 (CYP) isoforms with the following rank order: CYP3A > CYP2D6 > CYP2C9, CYP2C19 >> CYP2A6, CYP1A2, CYP2E1. There is some evidence that ritonavir may increase the activity of glucuronosyltransferases; thus, loss of therapeutic effects from directly glucuronidated agents during ritonavir therapy may signify the need for dosage alteration of these agents.

A systematic review of over 200 medications prescribed to HIV-infected patients was performed to identify potential drug interactions with ritonavir. There are a number of agents in which CYP3A or CYP2D6 partially contribute to the metabolism of the agent. In these cases, the magnitude of the interaction and therapeutic consequences cannot be predicted with any certainty.

When co-administering ritonavir with calcium channel blockers, immunosuppressants, some HMG-CoA reductase inhibitors (see **WARNINGS AND PRECAUTIONS** and **CONTRAINDICATIONS**), some steroids, or other substrates of CYP3A, or most antidepressants, certain antiarrhythmics, and some narcotic analgesics which are partially mediated by CYP2D6 metabolism, it is possible that substantial increases in concentrations of these other agents may occur, possibly requiring a dosage reduction (>50%); Examples are listed in **DRUG INTERACTIONS, Table 7 Predicted Drug Interactions: Use with Caution, Dose Decrease may be Needed**.

When co-administering ritonavir with any agent having a narrow therapeutic margin, such as anticoagulants, anticonvulsants, and antiarrhythmics, special attention is warranted. With some agents, the metabolism may be induced, resulting in decreased concentrations (see **DRUG INTERACTIONS, Table 7 Predicted Drug Interactions: Use with Caution, Dose Increase may be Needed**).

Drug-Drug Interactions

Table 4 and **Table 5** summarize the effects on AUC and C_{max} with 95% confidence intervals (95% CI) around the mean differences, of the co-administration of ritonavir with a variety of drugs. For information about clinical recommendations, see **DRUG INTERACTIONS, Table 6** and **Table 7**.

Effect of Co-Administered Drugs on Ritonavir

Table 4 Drug Interactions: Pharmacokinetic Parameters (AUC and C_{max}) for Ritonavir in the Presence of the Co-Administered Drug (see DRUG INTERACTIONS: Table 6 and Table 7 for Recommended Alterations in Dose or Regimen)						
Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Clarithromycin	500 mg q12h 4 days	200 mg q8h 4 days	22	↑ 12% (2, 23%)	↑ 15% (2, 28%)	↑ 14% (-3, 36%)
Didanosine	200 mg q12h 4 days, about 2.5 hrs before ritonavir	600 mg q12h 4 days	12	↔	↔	↔
Fluconazole	400 mg Day 1, 200 mg daily 4 days	200 mg q6h 4 days	8	↑ 12% (5, 20%)	↑ 15% (7, 22%)	↑ 14% (0, 26%)
Fluoxetine	30 mg q12h 8 days	600 mg single dose	16	↑ 19% (7, 34%)	↔	ND
Ketoconazole	200 mg daily 7 days	500 mg q12h 10 days	12	↑ 18% (-3, 52%)	↑ 10% (-11, 36%)	ND
Rifampin	600 mg or 300 mg daily 10days	500 mg q12h 20 days	7,9*	↓ 35% (7, 55%)	↓ 25% (-5, 46%)	↓ 49% (-14, 91%)
Voriconazole	400 mg q12h, 1 day; then 200 mg q12h 8 days	400 mg q12h 9 days	17	↔	↔	ND
Zidovudine	200 mg q8h 4 days	300 mg q6h 4 days	10	↔	↔	↔

↑ Indicates increase; ↓ indicates decrease; ↔ indicates no change.
 * Parallel group design; entries are subjects receiving combination and control regimens, respectively.

Effect of Ritonavir on Co-Administered Drugs

Table 5 Drug Interactions: Pharmacokinetic Parameters (AUC and C_{max}) for Co-Administered Drug in the Presence of Ritonavir (see DRUG INTERACTIONS: Table 6 and Table 7 for Recommended Alterations in Dose or Regimen)						
Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
<i>HIV-Antiviral Agents</i>						
Atazanavir	300 mg q24h days 1 to 20	100 mg q24h days 11 to 20	28	↑ 3.4 fold	↑ 1.9-fold	↑ 11.9-fold
Darunavir	800 mg single dose	Titration: 300 to 600 mg q12h over 6 days	8	↑ 9.2-fold	↑ 2-fold	not reported
Indinavir ¹	400 mg q12h 15 days	400 mg q12h 15 days	10	↑ 6% (-14, 29%) ↓ 7% (-22, 28%)	↓ 51% (40, 61%) ↓ 62% (52, 70%)	↑ 4-fold (2.8, 6.8X) ↑ 4-fold (2.5, 6.5X)

Table 5 Drug Interactions: Pharmacokinetic Parameters (AUC and C_{max}) for Co-Administered Drug in the Presence of Ritonavir (see DRUG INTERACTIONS: Table 6 and Table 7 for Recommended Alterations in Dose or Regimen)						
Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Saquinavir ²	400 mg q12h steady state	400 mg q12h steady-state	7	↑ 17-fold (9, 31X)	↑ 14-fold (7, 28X)	ND
Maraviroc	100 mg q12h	100 mg q12h	8	↑ 28%	↑ 161%	not reported
<i>Other agents</i>						
Alprazolam	1 mg single dose	500mg q12h 10 days	12	↓ 12% (-5, 30%)	↓ 16% (5, 27%)	ND
Clarithromycin	500 mg q12h 4 days	200 mg q8h 4 days	22	↑ 77% (56, 103%)	↑ 31% (15, 51%)	↑ 2.8-fold (2.4, 3.3X)
14-OH clarithromycin metabolite				↓ 100%	↓ 99%	↓ 100%
Desipramine	100 mg single dose	500 mg q12h 12 days	14	↑ 145% (103, 211%)	↑ 22% (12, 35%)	ND
2-OH desipramine metabolite				↓ 15% (3, 26%)	↓ 67% (62, 72%)	ND
Didanosine	200 mg q12h 4 days, about 2.5 hrs before ritonavir	600 mg q12h 4 days	12	↓ 13% (0, 23%)	↓ 16% (5, 26%)	↔
Ethinyl estradiol	50 mcg single dose	500 mg q12h 16 days	23	↓ 40% (31, 49%)	↓ 32% (24, 39%)	ND
Fluticasone propionate aqueous nasal spray	200 mcg daily 7 days	100 mg q12h 7 days	18	↑ approx. 350-fold ⁶	↑ approx. 25-fold ⁶	
Ketoconazole	200 mg daily 7 days	500 mg q12h 10 days	12	↑ 3.4-fold (2.8, 4.3X)	↑ 55% (40, 72%)	ND
Meperidine	50 mg oral single dose	500 mg q12h 10 days	8	↓ 62% (59, 65%)	↓ 59% (42, 72%)	ND
Normeperidine metabolite			6	↑ 47% (-24, 345%)	↑ 87% (42, 147%)	ND
Methadone ³	5 mg single dose	500 mg q12h 15 days	11	↓ 36% (16, 52%)	↓ 38% (28, 46%)	ND
Rifabutin	150 mg daily 16 days	500 mg q12h 10 days	5,11*	↑ 4-fold (2.8, 6.1X)	↑ 2.5-fold (1.9, 3.4X)	↑ 6-fold (3.5, 18.3X)
25-O-desacetyl rifabutin metabolite				↑ 38-fold (28, 56X)	↑ 16-fold (-13, 20X)	↑ 181-fold (ND)
Sildenafil	100 mg single dose	500 mg b.i.d. [†] 8 days	28	↑ 11-fold	↑ 4-fold	ND
Sulfamethoxazole ⁴	800 mg single dose	500 mg q12h 12 days	15	↓ 20% (16, 23%)	↔	ND
Tadalafil	20 mg single dose	200 mg q12h		↑ 124%	↔	ND

Table 5 Drug Interactions: Pharmacokinetic Parameters (AUC and C_{max}) for Co-Administered Drug in the Presence of Ritonavir (see DRUG INTERACTIONS: Table 6 and Table 7 for Recommended Alterations in Dose or Regimen)						
Co-Administered Drug	Dose of Co-Administered Drug	Ritonavir Dosage	n	AUC % (95% CI)	C _{max} % (95% CI)	C _{min} % (95% CI)
Theophylline	3 mg/kg q8h 15 days	500 mg q12h 10 days	13, 11*	↓ 43% (42, 45%)	↓ 32% (29, 34%)	↓ 57% (55, 59%)
Trazodone	50 mg single dose	200 mg q12h 10 days	10	↑ 2.4-fold	↑ 34%	
Trimethoprim ⁴	160 mg single dose	500 mg q12h 12 days	15	↑ 20% (3, 43%)	↔	ND
Vardenafil	5 mg	600 mg q12h		↑ 49-fold	↑ 13-fold	ND
Voriconazole	400 mg q12h, 1 day; then 200 mg q12h 8 days	400 mg q12h 9 days	17	↓ 82%	↓ 66%	
Warfarin	5 mg single dose	400 mg q12h 12 days	12	↑ 9% (-17, 44%) ⁵	↓ 9% (-16, -2%) ⁵	ND
S-Warfarin						
R-Warfarin				↓ 33% (-38, -27%) ⁵	↔	ND
Zidovudine	200 mg q8h 4 days	300 mg q6h 4 days	9	↓ 25% (15, 34%)	↓ 27% (4, 45%)	ND

1 Ritonavir and indinavir were co-administered for 15 days; Day 14 doses were administered after a 15%-fat breakfast (757 Kcal) and 9%-fat evening snack (236 Kcal), and Day 15 doses were administered after a 15%-fat breakfast (757 Kcal) and 32%-fat dinner (815 Kcal). Indinavir C_{min} was also increased 4-fold. Effects were assessed relative to an indinavir 800 mg q8h regimen under fasting conditions.
 2 Comparison to a standard saquinavir 600 mg q8h regimen (n=114).
 3 Effects were assessed on a dose normalized comparison to a methadone 20 mg single dose.
 4 Sulfamethoxazole and trimethoprim taken as single combination tablet.
 5 90% CI presented for R- and S-warfarin AUC and C_{max} ratios.
 6 This significant increase in plasma fluticasone propionate exposure resulted in a significant decrease (86%) in plasma cortisol AUC.
 ↑ Indicates increase; ↓ indicates decrease; ↔ indicates no change.
 ‡ Subjects in the entire study, a subset of subjects were administered the specified regimen.
 * Parallel group design; entries are subjects receiving combination and control regimens, respectively.
 † b.i.d. = twice daily

Alfuzosin: Based on results of a drug interaction study with ketoconazole, another potent inhibitor of CYP3A4, and alfuzosin, a significant increase in alfuzosin exposure is expected in the presence of ritonavir (600 mg twice daily). Therefore, alfuzosin should not be co-administered with ritonavir.

Amprenavir: Literature reports have shown that concentrations of the HIV-protease inhibitor, amprenavir, are increased when co-administered with ritonavir.

Digoxin: A literature report has shown that co-administration of ritonavir (300 mg every 12 hours) and digoxin resulted in significantly increased digoxin levels. Caution should be exercised when co-administering ritonavir and digoxin, with appropriate monitoring of serum levels.

Efavirenz: In healthy volunteers receiving 500 mg ritonavir twice daily with efavirenz 600 mg once daily, the steady state AUC was increased by 21%. An associated increase in the AUC of ritonavir of 17% was observed.

Tenofovir: Lopinavir/ritonavir has been shown to increase tenofovir concentrations. Higher tenofovir concentrations could potentiate tenofovir-associated adverse events, including renal disorders. Patients receiving ritonavir and tenofovir disoproxil fumarate should be monitored for tenofovir-associated adverse events. Refer to the VIREAD® (tenofovir) Product Monograph for more information.

Possible Dose Adjustments Based on Drug-Drug Interactions

Table 6 Established Drug Interactions: Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies or Predicted Interaction (see DRUG INTERACTIONS, Table 4 and Table 5 for Magnitude of Interaction)		
Concomitant Drug Class: Drug Name	Effect on Concentration of Ritonavir or Concomitant Drug	Clinical Comment
<i>HIV-Antiviral Agents</i>		
HIV Protease Inhibitor: atazanavir	When co-administered with reduced doses of atazanavir and ritonavir ↑ atazanavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Atazanavir plasma concentrations achieved with atazanavir 300 mg once daily and ritonavir 100 mg once daily are higher than those achieved with atazanavir 400 mg once daily. Refer to the atazanavir Product Monograph for details on co-administration of atazanavir 300 mg once daily, with ritonavir 100 mg once daily.
HIV Protease Inhibitor: darunavir	When co-administered with reduced doses of ritonavir ↑ darunavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Refer to the darunavir Product Monograph for details on co-administration darunavir 600 mg twice daily with ritonavir 100 mg twice daily.
HIV Protease Inhibitor: fosamprenavir	When co-administered with ritonavir ↑ amprenavir (↑ AUC, ↑ C _{max})	Refer to the fosamprenavir Product Monograph for details on co-administration fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily or fosamprenavir 1400 mg once daily with ritonavir 200 mg once daily.
HIV Protease Inhibitor: indinavir	When co-administered with reduced doses of indinavir and ritonavir ↑ indinavir (↔ AUC, ↓ C _{max} , ↑ C _{min})	Alterations in concentrations are noted when reduced doses of indinavir are co-administered with ritonavir. The safety and efficacy of this combination have not yet been established. The risk of nephrolithiasis may be increased when doses of indinavir equal to or greater than 800 mg b.i.d.† are given with ritonavir. Adequate hydration and monitoring of the patients is warranted.

<p align="center">Table 6 Established Drug Interactions: Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies or Predicted Interaction (see DRUG INTERACTIONS, Table 4 and Table 5 for Magnitude of Interaction)</p>		
Concomitant Drug Class: Drug Name	Effect on Concentration of Ritonavir or Concomitant Drug	Clinical Comment
HIV Protease Inhibitor: saquinavir	When co-administered with reduced doses of saquinavir and ritonavir ↑ saquinavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	The recommended dosage regimen is saquinavir 1000 mg with ritonavir 100 mg twice daily taken within 2 hours after a meal. Dose adjustment may be needed if other HIV-protease inhibitors are used in combination with saquinavir and ritonavir. Saquinavir and ritonavir should not be given together with rifampin due to risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the three drugs are given together. In some cases, co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre-existing liver disease. Refer to the INVIRASE® Product Monograph for prescribing information.
HIV Protease Inhibitor: nelfinavir	↑ M8 (major active metabolite of nelfinavir; ↑ AUC)	Interactions between ritonavir and nelfinavir are likely to involve cytochrome P450 inhibition and induction.
HIV Protease Inhibitor: tipranavir	When co-administered with ritonavir ↑ tipranavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	Refer to the tipranavir Product Monograph for details on co-administration of tipranavir 500 mg twice daily with ritonavir 200 mg twice daily.
Nucleoside Reverse Transcriptase Inhibitor: didanosine		Dosing of didanosine and ritonavir should be separated by 2.5 hours to avoid formulation incompatibility.
Non-Nucleoside Reverse Transcriptase Inhibitor: delavirdine	↑ ritonavir (↑ AUC, ↑ C _{max} , ↑ C _{min})	When used in combination with delavirdine, a dose reduction of ritonavir should be considered. Based on comparison to historical data, the pharmacokinetics of delavirdine did not appear to be affected by ritonavir. The safety and efficacy of this combination (delavirdine/ritonavir) have not been established.
CCR5 Antagonist: maraviroc	When co-administered with reduced dose of ritonavir ↑ maraviroc (↑ AUC, ↑ C _{max})	Refer to the maraviroc Product Monograph for details on co-administration of maraviroc 150 mg twice daily with ritonavir.
<i>Other agents</i>		
Anesthetic: meperidine	↓ meperidine ↑ normeperidine (metabolite)	Dosage increase and long-term use of meperidine with ritonavir are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g., seizures).

<p align="center">Table 6 Established Drug Interactions: Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies or Predicted Interaction (see DRUG INTERACTIONS, Table 4 and Table 5 for Magnitude of Interaction)</p>		
Concomitant Drug Class: Drug Name	Effect on Concentration of Ritonavir or Concomitant Drug	Clinical Comment
Antialcoholics: disulfiram/metronidazole		Ritonavir formulations contain alcohol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole).
Antibacterial: fusidic acid	↑ fusidic acid ↑ ritonavir	
Anticancer agents: vincristine, vinblastine	↑ Anticancer agents	Serum concentrations may be increased when co-administered with ritonavir resulting in the potential for increased incidence of adverse events.
Anticoagulant: warfarin	↓ R-warfarin ↓ ↑ S-warfarin	Initial frequent monitoring of the INR during ritonavir and warfarin co-administration is indicated.
Antidepressant : desipramine	↑ desipramine	Dosage reduction and concentration monitoring of desipramine is recommended.
Antidepressant: bupropion	↓ bupropion	Bupropion is primarily metabolized by CYP2B6. Concurrent administration of bupropion with repeated doses of ritonavir is expected to decrease bupropion levels.
Antidepressant: trazodone	↑ trazodone	Concomitant use of ritonavir and trazodone increases concentrations of trazodone. Adverse events of nausea, dizziness, hypertension and syncope have been observed. If trazodone is used with a CYP3A4 inhibitor such as ritonavir, the combination should be used with caution and a lower dose of trazodone should be considered.
Antifungal : ketoconazole, itraconazole	↑ ketoconazole ↑ itraconazole	High doses of ketoconazole or itraconazole (> 200 mg/day) are not recommended.
Anti-infective: clarithromycin	↑ clarithromycin	For patients with renal impairment, the following dosage adjustments should be considered: For patients with CL _{CR} 30 to 60 mL/min, the dose of clarithromycin should be reduced by 50%. For patients with CL _{CR} < 30 mL/min, the dose of clarithromycin should be reduced by 75%. No dose adjustment for patients with normal renal function is necessary.
Antimycobacterial: rifabutin	↑ rifabutin and rifabutin metabolite	Dosage reduction of rifabutin by at least three-quarters of the usual dose of 300 mg/day is recommended (e.g., 150 mg every other day or three times a week). Further dosage reduction may be necessary.
Antimycobacterial: rifampin	↓ ritonavir	May lead to loss of virologic response. Alternate antimycobacterial agents such as rifabutin should be considered (see Antimycobacterial: rifabutin, for dose reduction recommendations).
Bronchodilator: theophylline	↓ theophylline	Increased dosage of theophylline may be required; therapeutic monitoring should be considered.

<p align="center">Table 6 Established Drug Interactions: Alteration in Dose or Regimen Recommended Based on Drug Interaction Studies or Predicted Interaction (see DRUG INTERACTIONS, Table 4 and Table 5 for Magnitude of Interaction)</p>		
Concomitant Drug Class: Drug Name	Effect on Concentration of Ritonavir or Concomitant Drug	Clinical Comment
Erectile Dysfunction (PDE5 Inhibitors): sildenafil	↑ sildenafil	Sildenafil should not exceed a maximum single dose of 25 mg in a 48-hour period in patients receiving concomitant ritonavir therapy (see WARNINGS AND PRECAUTIONS).
Tadalafil	↑ tadalafil	Tadalafil may be used with caution at reduced doses of no more than 10 mg every 72 hours with increased monitoring for adverse events.
Vardenafil	↑ vardenafil	Vardenafil should not be used with ritonavir.
Hypolipidemics, HMG-CoA Reductase Inhibitors: atorvastatin, rosuvastatin	↑ atorvastatin ↑ rosuvastatin	Co-administration with lovastatin and simvastatin is not recommended (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, General, HMG-CoA Reductase Inhibitors). Use the lowest possible dose of atorvastatin or rosuvastatin with careful monitoring or consider other HMG-CoA reductase inhibitors such as pravastatin or fluvastatin in combination with ritonavir.
Immunosuppressants: cyclosporine, everolimus, tacrolimus, rapamycin	↑ immunosuppressants	Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir.
Inhaled Steroid: fluticasone propionate	↑ fluticasone	Concomitant use of fluticasone propionate and ritonavir may significantly increase fluticasone propionate plasma concentrations and reduce serum cortisol concentrations. Co-administration of fluticasone propionate and ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. Consider alternatives to fluticasone propionate, particularly for long-term use (see WARNINGS AND PRECAUTIONS, General, Corticosteroids).
Narcotic Analgesic: methadone	↓ methadone	Dosage increase of methadone may be considered.
Oral Contraceptive or Patch Contraceptive: ethinyl estradiol	↓ ethinyl estradiol	Dosage increase or alternate contraceptive measures should be considered.
† b.i.d. = twice daily		

Possible Dose Adjustments Based on Predicted Drug-Drug Interactions

Table 7 Predicted Drug Interactions: Use with Caution, Dose Adjustment of Co-administered Drug may be Needed (see WARNINGS AND PRECAUTIONS)	
Drug Class	Examples of Drugs
<i>Examples of Drugs in which Plasma Concentrations may be <u>Increased</u> by Co-administration with Ritonavir</i> <u>Dose Decrease of Co-administered Drug may be Needed</u>	
Analgesics, narcotics	tramadol, propoxyphene
Antiarrhythmics	disopyramide, lidocaine, mexiletine
Anticonvulsants	carbamazepine, clonazepam, ethosuximide
Antidepressants, tricyclic	amitriptyline, clomipramine, imipramine, maprotiline, nortriptyline, trimipramine
Antidepressants, SSRIs and non-tricyclics	nefazodone, sertraline, fluoxetine, paroxetine, venlafaxine
Antiemetics	dronabinol
Antiparasitics	quinine
Beta-blockers	metoprolol, timolol
Calcium channel blockers	diltiazem, nifedipine, verapamil
Neuroleptics	perphenazine, risperidone, thioridazine
Sedative/hypnotics	bupirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem
Steroids	dexamethasone, prednisone
Stimulants	methamphetamine
HIV Antivirals	atazanavir, darunavir, (fos)amprenavir, tipranavir, maraviroc
<i>Examples of Drugs in which Plasma Concentrations may be <u>Decreased</u> by Co-Administration with Ritonavir</i> <u>Dose Increase of Co-administered Drug may be Needed</u>	
Anticonvulsants	divalproex, lamotrigine, phenytoin
Antiparasitics	atovaquone

Drug-Food Interactions

It is recommended that ritonavir be taken with meals, if possible. Refer to **ACTION AND CLINICAL PHARMACOLOGY, Absorption** and to **CLINICAL TRIALS, Comparative Bioavailability Studies** for information on the effect of food of ritonavir pharmacokinetics.

Drug-Herb Interactions

St-John's Wort

Concomitant use of ritonavir and St. John's wort (*Hypericum perforatum*) or products containing St. John's wort is not recommended. Co-administration of protease inhibitors, including ritonavir, with St. John's wort is expected to substantially decrease protease inhibitor concentrations and may result in sub-optimal levels of ritonavir and lead to loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors (see **CONTRAINDICATIONS**).

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Patients should be aware that frequently observed adverse events, such as mild to moderate gastrointestinal disturbances and paraesthesias, may diminish as therapy is continued. In addition, patients initiating combination regimens with ritonavir and other antiretroviral agents may improve gastrointestinal tolerance by initiating ritonavir alone and subsequently adding the other antiretroviral agents before completing two weeks of ritonavir monotherapy. The long-term effects of dose escalation on efficacy have not been established.

Recommended Dose and Dosage Adjustment

Adult Patients

The recommended dosage of ritonavir is 600 mg (6 capsules or 7.5 mL) twice daily orally. Some patients experience nausea upon initiation of 600 mg twice daily dosing. Use of a dose titration schedule may help to reduce treatment-emergent adverse events while maintaining appropriate ritonavir plasma levels. Ritonavir should be started at no less than 300 mg twice daily and increased by 100 mg twice daily increments up to 600 mg twice daily. The titration period should not exceed 14 days.

Pediatric Patients

Ritonavir should be used in combination with other antiretroviral agents. The recommended dosage of ritonavir is 400 mg/m² of body surface area twice daily by mouth and should not exceed 600 mg twice daily (**Table 8**). Ritonavir should be started at 250 mg/m² twice daily and increased at 2- to 3-day intervals by 50 mg/m² twice daily, as tolerated. If patients do not tolerate 400 mg/m² twice daily due to adverse events, the highest tolerated dose should be used for maintenance therapy in combination with other antiretroviral agents. When possible, doses should be administered using a calibrated dosing syringe.

Body Surface Area * (m²)	Twice Daily Dose 250 mg/m²	Twice Daily Dose 300 mg/m²	Twice Daily Dose 350 mg/m²	Twice Daily Dose 400 mg/m²
0.25	0.8 mL (62.5 mg)	0.9 mL (75 mg)	1.1 mL (87.5 mg)	1.25 mL (100 mg)
0.50	1.6 mL (125 mg)	1.9 mL (150 mg)	2.2 mL (175 mg)	2.5 mL (200 mg)
0.75	2.3 mL (187.5 mg)	2.8 mL (225 mg)	3.3 mL (262.5 mg)	3.75 mL (300 mg)
1.00	3.1 mL (250 mg)	3.75 mL (300 mg)	4.4 mL (350 mg)	5 mL (400 mg)
1.25	3.9 mL (312.5 mg)	4.7 mL (375 mg)	5.5 mL (437.5 mg)	6.25 mL (500 mg)
1.50	4.7 mL (375 mg)	5.6 mL (450 mg)	6.6 mL (525 mg)	7.5 mL (600 mg)

Table 8 Pediatric Dosage Guidelines				
Body Surface Area* (m ²)	Twice Daily Dose 250 mg/m ²	Twice Daily Dose 300 mg/m ²	Twice Daily Dose 350 mg/m ²	Twice Daily Dose 400 mg/m ²
* Body surface area can be calculated with the following equation:				
BSA (m ²) =	$\sqrt{\frac{\text{Ht (Cm)} \times \text{Wt (kg)}}{3600}}$			

Missed Dose

If a dose of ritonavir is missed, patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped, the patient should not double the next dose.

Administration

NORVIR[®] (ritonavir oral solution) and NORVIR[®] SEC (ritonavir soft elastic capsules) are administered orally. It is recommended that ritonavir be taken with meals if possible. Patients may improve the taste of ritonavir oral solution by mixing with chocolate milk or ENSURE[®] within one hour of dosing. The effects of antacids on the absorption of ritonavir have not been studied.

The ritonavir solution dosage cup should be cleaned immediately with hot water and dish soap after use. When cleaned immediately, drug residue is removed. The dosage cup **must** be dry prior to use.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Acute Overdosage

Human Overdose Experience: Human experience of acute overdose with NORVIR[®] (ritonavir oral solution) and NORVIR[®] SEC (ritonavir soft elastic capsules) is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased.

A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose.

Management of Overdosage

Administration of activated charcoal may be used to aid in removal of unabsorbed drug. Treatment of overdose with ritonavir consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with ritonavir. Since ritonavir is extensively metabolized by the liver and is highly protein-bound, dialysis is unlikely to be beneficial in significant removal of the drug. A Certified Poison Control Centre should be consulted for up-to-date information on the management of overdose with ritonavir.

NORVIR[®] Oral Solution contains 43% alcohol by volume. Accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Ritonavir is an inhibitor of HIV protease with activity against the Human Immunodeficiency Virus (HIV).

Ritonavir is an orally active peptidomimetic inhibitor of both the HIV-1 and HIV-2 proteases. Inhibition of HIV protease renders the enzyme incapable of processing the *gag-pol* polyprotein precursor which leads to the production of HIV particles with immature morphology that are unable to initiate new rounds of infection. Ritonavir has selective affinity for the HIV protease and has little inhibitory activity against human aspartyl proteases.

Antiviral Activity *in vitro*

The activity of ritonavir was assessed *in vitro* in acutely infected lymphoblastoid cell lines and in peripheral blood lymphocytes. The concentration of drug that inhibits 50% (EC₅₀) of viral replication ranged from 3.8 to 153 nM depending upon the HIV-1 isolate and the cells employed. The average EC₅₀ for low passage clinical isolates was 22 nM (n=13). In MT₄ cells, ritonavir demonstrated additive effects against HIV-1 in combination with either zidovudine (ZDV) or didanosine (ddI). Studies which measured cytotoxicity of ritonavir on several cell lines showed that > 20 µM was required to inhibit cellular growth by 50% resulting in an *in vitro* therapeutic index of at least 1000.

Resistance

HIV-1 isolates with reduced susceptibility to ritonavir have been selected *in vitro*. The clinical relevance of phenotypic and genotypic changes associated with ritonavir therapy has not been established (see **WARNINGS AND PRECAUTIONS** and **MICROBIOLOGY**).

Cross-resistance to Other Antiretrovirals

Among protease inhibitors variable cross-resistance has been recognized (see **WARNINGS AND PRECAUTIONS** and **MICROBIOLOGY**).

Cross-resistance between ritonavir and reverse transcriptase inhibitors is unlikely because of the different enzyme targets involved. One ZDV-resistant HIV isolate tested *in vitro* retained full susceptibility to ritonavir.

Pharmacodynamics

In vitro data indicate that ritonavir is active against all strains of HIV tested in a variety of transformed and primary human cell lines. The concentration of drug that inhibits 50% and 90% (EC₅₀, EC₉₀) of viral replication is approximately 0.02 and 0.11 μM, respectively. Studies which measured direct cell toxicity of ritonavir on several cell lines showed no direct toxicity at concentrations up to 25 μM, with a resulting *in vitro* therapeutic index of at least 1000.

Pharmacokinetics

The pharmacokinetics of ritonavir have been studied in healthy volunteers and HIV-infected patients (CD₄ ≥ 50 cells/μL). See **Table 9** for ritonavir pharmacokinetic characteristics.

Table 9 Ritonavir Pharmacokinetic Characteristics		
Parameter	n	Values (Mean ± SD)
C _{max} SS [¶]	10	11.2 ± 3.6 mcg/mL
C _{trough} SS [¶]	10	3.7 ± 2.6 mcg/mL
V _β /F [§]	91	0.41 ± 0.25 L/kg
t _{1/2}		3 to 5 h
CL/F SS [¶]	10	8.8 ± 3.2 L/h
CL/F [§]	91	4.6 ± 1.6 L/h
CL _R	62	< 0.1 L/h
RBC/Plasma Ratio		0.14
Percent Bound*		98 to 99%

¶ SS = steady state; patients taking ritonavir 600 mg q12h.
§ Single ritonavir 600 mg dose.
* Primarily bound to human serum albumin and alpha-1 acid glycoprotein over the ritonavir concentration range of 0.01 to 30 mcg/mL.

Absorption: The absolute bioavailability of ritonavir has not been determined. After a 600 mg dose of oral solution, peak concentrations of ritonavir were achieved approximately 2 hours and 4 hours after dosing under fasting and non-fasting (514 KCal; 9% fat, 12% protein, and 79% carbohydrate) conditions, respectively.

Effect of Food on Oral Absorption

When the oral solution was given under non-fasting conditions, peak ritonavir concentrations

decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of oral solution, within one hour of administration, with 240 mL of chocolate milk, ADVERA[®] or ENSURE[®] did not significantly affect the extent and rate of ritonavir absorption. After a single 600 mg dose under non-fasting conditions, in two separate studies, the capsule (n=21) and oral solution (n=18) formulations yielded mean \pm SD areas under the plasma concentration-time curve (AUCs) of 129.5 ± 47.1 and 129.0 ± 39.3 mcg·h/mL, respectively. Relative to fasting conditions, the extent of absorption of ritonavir from the capsule formulation was 15% higher when administered with a meal (771 KCal; 46% fat, 18% protein, and 37% carbohydrate).

Distribution: The protein binding of ritonavir in human plasma was noted to be approximately 98 to 99%. Ritonavir binds to both human α -1-acid glycoprotein (AAG) and human serum albumin (HSA) with comparable affinities. Total plasma protein binding is constant over the concentration range of 1-100 mcg/mL.

Tissue distribution studies with ¹⁴C-labeled ritonavir in rats showed the liver, adrenals, pancreas, kidneys and thyroid to have the highest concentrations of drug. Tissue to plasma ratios of approximately one, measured in rat lymph nodes, suggests that ritonavir distributes into lymphatic tissue. Ritonavir penetrates minimally into the brain.

Metabolism: Nearly all of the plasma radioactivity after a single oral 600 mg dose of ¹⁴C-ritonavir oral solution (n=5) was attributed to unchanged ritonavir. Five ritonavir metabolites have been identified in human urine and feces. The isopropyl thiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of parent drug; however, the concentrations of this metabolite in plasma are low. Studies utilizing human liver microsomes have demonstrated that cytochrome P450 3A (CYP3A) is the major isoform involved in ritonavir metabolism, although CYP2D6 also contributes to the formation of M-2.

Excretion: In a study of five subjects receiving a 600 mg dose of ¹⁴C-ritonavir oral solution, $11.3 \pm 2.8\%$ of the dose was excreted into the urine, with $3.5 \pm 1.8\%$ of the dose excreted as unchanged parent drug. In that study, $86.4 \pm 2.9\%$ of the dose was excreted in the feces with $33.8 \pm 10.8\%$ of the dose excreted as unchanged parent drug. Upon multiple dosing, ritonavir accumulation is less than predicted from a single dose possibly due to a time and dose-related increase in clearance.

Effects on the Electrocardiogram

QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once-daily) controlled cross-over study in 45 healthy adults, with 10 measurements over 12 hours on Day 3. The maximum mean (95% upper confidence bound) difference in QTcF from placebo was 5.5 (7.6) msec for 400 mg twice-daily ritonavir. The Day 3 ritonavir exposure was approximately 1.5 fold higher than that observed with the 600 mg twice-daily dose at steady state. No subject experienced an increase in QTcF of ≥ 60 msec from baseline or a QTcF interval exceeding the potentially clinically relevant threshold of 500 msec.

Mean change from baseline in PR interval of 11.0-24.0 msec was also noted in subjects receiving

ritonavir in the same study on Day 3. Maximum PR interval was 252 msec and no second or third degree heart block was observed. (See **WARNINGS and PRECAUTIONS**).

Special Populations and Conditions

Pediatrics: The pharmacokinetic profile of ritonavir in pediatric patients below the age of 2 years has not been established. Steady-state pharmacokinetics were evaluated in 37 HIV-infected patients ages 2 to 14 years receiving doses ranging from 250 mg/m² twice daily to 400 mg/m² twice daily. Across dose groups, ritonavir steady-state oral clearance (CL/F/m²) was approximately 1.5 times faster in pediatric patients than in adult subjects. Ritonavir concentrations obtained after 350 to 400 mg/m² twice daily in pediatric patients were comparable to those obtained in adults receiving 600 mg (approximately 330 mg/m²) twice daily.

Geriatrics: No age-related pharmacokinetic differences have been observed in adult patients (18 to 63 years). Ritonavir pharmacokinetics have not been studied in older patients.

Gender: A study of ritonavir pharmacokinetics in healthy males and females showed no statistically significant differences in the pharmacokinetics of ritonavir.

Race: Pharmacokinetic differences due to race have not been identified.

Weight: Ritonavir pharmacokinetic parameters were not statistically significantly associated with body weight or lean body mass.

Hepatic Insufficiency: In six HIV-infected adult subjects with mild hepatic insufficiency dosed with ritonavir 400 mg twice daily, ritonavir exposures were similar to control subjects dosed with 500 mg twice daily. Results indicate that dose adjustment is not required in patients with mild hepatic impairment. Adequate pharmacokinetic data are not available for patients with moderate hepatic impairment. Protein binding of ritonavir was not statistically significantly affected by mild or moderately impaired hepatic function.

Renal Insufficiency: Ritonavir pharmacokinetics have not been studied in patients with renal insufficiency; however, since renal clearance is negligible, a decrease in total body clearance is not expected in patients with renal insufficiency.

Because ritonavir is highly protein bound it is unlikely that ritonavir will be significantly removed by dialysis (see **OVERDOSAGE**).

STORAGE AND STABILITY

Soft Elastic Capsules

Store NORVIR[®] SEC (soft elastic capsules) in the refrigerator between 2 and 8°C (36 to 46°F) until dispensed. Refrigeration of NORVIR[®] SEC by the patient is recommended, but not

required if used within 30 days and stored below 25°C (77°F). Protect from light. Avoid exposure to excessive heat. Product must be stored and dispensed in the original container.

Oral Solution

Store NORVIR[®] (ritonavir oral solution) at room temperature, between 20 and 25°C (68 to 77°F). **Do not refrigerate. SHAKE WELL BEFORE EACH USE.** Product must be stored and dispensed in the original container. Avoid exposure to excessive heat. Keep cap tightly closed. Use by product expiration date.

The ritonavir oral solution dosage cup should be cleaned immediately with hot water and dish soap after use. When cleaned immediately, drug residue is removed. The dosage cup **must** be dry prior to use.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Ritonavir is available as 100 mg soft elastic capsules and 80 mg/mL oral solution for oral administration.

Composition

Soft Elastic Capsules

Each white oblong soft elastic capsule contains 100 mg of ritonavir for oral administration. Non-medicinal ingredients include: butylated hydroxytoluene, ethanol, gelatin, black opacode ink (iron oxide), oleic acid, polyoxyl 35 castor oil, purified water, titanium dioxide, sorbitol and glycerin.

Oral Solution

Each mL of orange-colored oral solution in a peppermint and caramel-flavored vehicle contains 80 mg of ritonavir for oral administration. Non-medicinal ingredients include: ethanol, water, polyoxyl 35 castor oil, propylene glycol, anhydrous citric acid to adjust pH, saccharin sodium, peppermint oil, creamy caramel flavoring, and FD&C Yellow No. 6.

Availability Of Dosage Forms

Soft Elastic Capsules

NORVIR[®] SEC (ritonavir soft elastic capsules) 100 mg is available in HDPE bottles of 120 capsules.

Each 100 mg white oblong soft elastic capsule is imprinted with the Abbott logo, 100, and the Abbo-Code DS.

Oral Solution

NORVIR[®] (ritonavir oral solution) 80 mg/mL is available in amber-colored, multi-dose bottles containing 600 mg ritonavir per 7.5 mL marked dosage cup (80 mg/mL) in 240 mL bottles.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: Ritonavir

Chemical name: 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]

Molecular formula and molecular mass: C₃₇H₄₈N₆O₅S₂ 720.95

Structural formula:



Physicochemical properties: Ritonavir is a white to light tan powder. Ritonavir has a bitter metallic taste. It is freely soluble in methanol and ethanol, soluble in isopropanol and practically insoluble in water.

CLINICAL TRIALS

The activity of NORVIR[®] (ritonavir) as monotherapy or in combination with nucleoside reverse transcriptase inhibitors has been evaluated in 1446 patients enrolled in two double-blind, randomized trials. Ritonavir therapy in combination with zidovudine and zalcitabine was also evaluated in an open-label, non-comparative study of 32 patients.

Study Demographics and Trial Design

Table 10 Summary Of Patient Demographics For Clinical Trials In Specific Indications							
	Study #	Trial Design	Dosage, Route of Administration and Duration	Study Subjects	Mean Age (Range)	Gender (% M/F) (%C/O) ¹	Mean Baseline CD ₄ Cell Count (Range)
Advanced Patients with Prior Antiretroviral Therapy	M94-247	Double blind, randomized, two-arm, parallel, multicenter international	Ritonavir liquid or semi-solid capsules (600 mg b.i.d. [†]) vs. Placebo Oral 6 months double-blind followed by 14 months open-label follow-up	1090	38.9 years (15-72)	92/8 86/14	32 cells/μL (0-154) ²
Patients Without Prior Antiretroviral Therapy	M94-245	Double blind, randomized, three-arm, parallel, multicenter	Ritonavir liquid or semi-solid capsules (600 mg b.i.d. [†]) vs. Zidovudine capsules (200 mg t.i.d. [†]) vs. Ritonavir liquid or semi-solid capsules (600 mg b.i.d. [†]) + Zidovudine capsules (200 mg t.i.d. [†]) Oral 8-12 months	356	36.0 years (18-69)	91/9 83/17	364 cells/μL Range: 139-1054 (200-500) ³
Combination Therapy in Anti-retroviral Naïve Patients	M94-208	Phase II, open-label, multicenter	Triple Therapy Combination: Ritonavir (600 mg b.i.d. [†]) + Zidovudine (200 mg t.i.d. [†]) + Zalcitabine (0.75 mg t.i.d. [†]) Oral 6 months	32	38.1 years (29-52)	88/12 97/3	Median: 83 > 100 cells/μL (81%) ⁴
<p>1 % Male/Female; % Caucasian/Other</p> <p>2 Approximately 50% of patients had baseline CD₄ cell counts ≤ 20 cells/μL, and only 22% had counts > 50 cells/μL.</p> <p>3 Approximately 75% of the patients were evenly distributed between this range</p> <p>5 The majority (81%) of patients had baseline CD₄ values > 100 cells/μL</p> <p>† b.i.d. = twice daily; t.i.d. = three times daily</p>							

Study Results

Advanced Patients with Prior Antiretroviral Therapy

Study 247 was a randomized, double-blind trial conducted in HIV-infected patients with at least nine months of prior antiretroviral therapy and baseline CD₄ cells counts ≤ 100 cells/ μ L. Ritonavir 600 mg twice daily or placebo was added to each patient's baseline antiretroviral therapy regimen, which could have consisted of up to two approved antiretroviral agents. The study accrued 1090 patients, with mean baseline CD₄ cell count at study entry of 32 cells/ μ L. Median duration of follow-up was 6 months.

The six month cumulative incidence of clinical disease progression or death was 17% for patients randomized to ritonavir compared to 34% for patients randomized to placebo. This difference in rates was statistically significant (see **Figure 1**).




Figure 1: Time to Disease Progression or Death in Study 247

The six-month cumulative mortality was 5.8% for patients randomized to ritonavir and 10.1% for patients randomized to placebo. This difference in rates was statistically significant.

In addition, analyses of mean CD₄ cell count changes from baseline over the first 16 weeks of study for the first 211 patients enrolled (mean baseline CD₄ cell count = 29 cells/ μ L) showed that ritonavir was associated with larger increases in CD₄ cell counts than was placebo (see **Figure 2**).




Figure 2: Mean CD₄ Count Changes (cells/μL) From Baseline in Study 247

Figure 3 summarizes the mean changes from baseline in log HIV RNA levels for Study 247.




Figure 3: Mean Change From Baseline in Log HIV RNA Levels In Study 247

1 The clinical significance of changes in HIV RNA measurements has not been established.

Patients Without Prior Antiretroviral Therapy

In Study 245, 356 antiretroviral-naive HIV-infected patients (mean baseline CD₄ = 364 cells/ μ L) were randomized to receive either ritonavir 600 mg twice daily, zidovudine 200 mg-three times daily, or a combination of these drugs. In analyses of average CD₄ cell count changes from baseline over the first 16 weeks of study, both ritonavir monotherapy and combination therapy produced greater mean increases in CD₄ cell count than did zidovudine monotherapy (see **Figure 4**). The CD₄ cell count increases for ritonavir monotherapy were larger than the increases for combination therapy.




Figure 4: Mean CD₄ Count Changes (cells/ μ L) From Baseline in Study 245

Figure 5 summarizes the mean changes from baseline in log HIV RNA levels for Study 245.




Figure 5: Mean Change From Baseline in Log HIV RNA Levels in Study 245

Combination Therapy with Ritonavir, Zidovudine, and Zalcitabine in Antiretroviral-Naive Patients

In Study 208, an open-label uncontrolled trial, 32 antiretroviral-naive HIV-infected patients initially received ritonavir 600 mg twice daily monotherapy. Zidovudine 200 mg three times daily and zalcitabine 0.75 mg three times daily were added after 14 days of ritonavir monotherapy. Results of combination therapy for the first 20 weeks of this study show median increases in CD₄ cell counts from baseline levels of 83 to 106 cells/ μ L over the treatment period. Mean decreases from baseline in HIV RNA particle levels ranged from 1.69 to 1.92 logs.

Comparative Bioavailability Studies

In a Phase I, randomized, single-dose, fasting and non-fasting, open-label, three-period, crossover study, a total of 57 healthy adult male and female volunteers were randomly assigned to three dosing regimens to assess the bioequivalence of 600 mg ritonavir dosed as six 100 mg soft elastic capsules to 7.5 mL of 80 mg/mL ritonavir oral solution. **Table 11** summarizes the comparative bioavailability data.

Table 11 Comparative Bioavailability Data for the 100 mg Ritonavir Soft Elastic Capsule versus the 80 mg/mL Ritonavir Oral Solution				
PARAMETER	REFERENCE Non-fasting - Regimen A (n = 57)	TEST Non-Fasting - Regimen B (n = 57)	TEST Fasting - Regimen C (n = 57)	% RATIO/RATIO OF GEOMETRIC MEANS
AUC _t (mcg·h/mL)	77.0 109.3 (54.4)	104.2 121.4 (44.2)	93.3 108.5 (47.7)	B/A = 135.4 C/B = 89.5
AUC ₄₀ (mcg·h/mL)	77.1 109.3 (54.4)	104.2 121.4 (44.2)	93.3 108.5 (47.7)	B/A = 135.3 C/B = 89.5
AUC _{inf} (mcg·h/mL)	77.2 109.6 (54.5)	104.6 121.7 (44.2)	93.5 108.5 (47.7)	B/A = 135.4 C/B = 89.4
C _{max} (mcg/mL)	8.8 11.9 (44.6)	11.91 13.6 (39.5)	12.73 14.5 (40.2)	B/A = 135.3 C/B = 107.0
T _{max} ^a (h)	3.8 4.1 (38.4)	5.2 5.5 (35.9)	3.9 4.4 (70.2)	B/A = 138.3 C/B = 74.0
T _{1/2} ^b (h)	4.31 4.23 (20.0)	4.04 3.96 (23.3)	4.30 4.21 (21.7)	B/A = 93.6 C/B = 106.6
Beta h ⁻¹	0.161 0.164 (20.0)	0.172 0.175 (18.5)	0.161 0.165 (21.9)	B/A = 106.8 C/B = 93.8
CL/F (L/h)	6.8 28.0 (405.5)	5.7 9.8 (260.3)	6.4 12.7 (357.6)	B/A = 83.8 C/B = 111.8
Regimen A: 600 mg ritonavir as 7.5 mL (80 mg/mL) liquid, reference, non-fasting (Market formulation K-5). Regimen B: 600 mg ritonavir as six 100 mg SEC, test, non-fasting, formulation 2. Regimen C: 600 mg ritonavir as six 100 mg SEC, test, fasting, formulation 2.				
a T _{max} : Expressed as arithmetic mean (%CV) only.				
b t _{1/2} : Expressed as harmonic mean only.				

DETAILED PHARMACOLOGY

Pharmacodynamics

Animal Data

Ritonavir was administered orally to mice or rats at doses of 5 to 50 mg/kg to determine potential effects on various neuropharmacological endpoints. In mice, ritonavir had no meaningful effect on rotarod performance, ethanol-induced sleep time or pentobarbital-induced sleep time. In rats, no effect was observed on spontaneous motor activity or rotarod performance.

Ritonavir produced no pharmacologically significant effects on heart rate or blood pressure when administered orally to unanesthetized rats at doses of 20 or 50 mg/kg. The compound was also infused intravenously in a vehicle consisting of 20% ethanol and 15% propylene glycol in 5% dextrose water to pentobarbital-anesthetized dogs instrumented to measure various cardiovascular parameters.

Mean peak plasma levels of ritonavir were as high as 15.11 mcg/mL. Although the vehicle itself produced hemodynamic changes consistent with cardiac depression, ritonavir produced no consistent additional effects on systemic or pulmonary pressures or resistance, central venous pressure, cardiac output, left ventricular dP/dt or end-diastolic pressure.

Ritonavir had no effect on isolated guinea pig ileum basal tone or on carbachol-induced contractions.

Clinical Data

A phase 1, multiple-dose, open-label, placebo and active controlled (moxifloxacin 400 mg QD), randomized study was conducted according to a crossover design in healthy volunteers. RTV was dosed at 400 mg BID. On Day 3, RTV concentrations were approximately 1.5 fold higher than that observed with the 600 mg twice-daily dose at steady state. Digital EKGs were performed in triplicate on study Day 3 and compared to time-matched baseline EKGs. At these increased concentrations, the maximum increase in QTcF was 5.5 msec with an upper bound 95% CI of 7.6 msec. This increase is not clinically significant.

The absolute PR interval on Day 3 and change from baseline were also evaluated. The maximum PR interval was 252 msec and no second or third degree heart block was observed. Exposure-response analysis predicted that the PR effect of RTV plateaus around 20 msec, thus ritonavir 600 mg BID is unlikely to result in clinically significant PR prolongation.

Pharmacokinetics

For details regarding the ritonavir pharmacokinetics refer to section **ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics**.

MICROBIOLOGY

Resistance

HIV-1 isolates with reduced susceptibility to ritonavir have been selected *in vitro*. Genotypic analysis of these isolates showed mutations in the HIV protease gene at amino acid positions 84 (Ile to Val), 82 (Val to Phe), 71 (Ala to Val), and 46 (Met to Ile). Phenotypic (n=18) and genotypic (n=44) changes in HIV isolates from selected patients treated with ritonavir were monitored in Phase I/II trials over a period of 3 to 32 weeks. Mutations associated with the HIV viral protease in isolates obtained from 41 patients appeared to occur in a stepwise and ordered fashion; in sequence, these mutations were position 82 (Val to Ala/Phe), 54 (Ile to Val), 71 (Ala to Val/Thr), and 36 (Ile to Leu), followed by combinations of mutations at an additional 5 specific amino acid positions.

Of 18 patients for which both phenotypic and genotypic analysis were performed on free virus isolated from plasma, 12 showed reduced susceptibility to ritonavir *in vitro*. All 18 patients possessed one or more mutations in the viral protease gene. The 82 mutation appeared to be necessary but not sufficient to confer phenotypic resistance. Phenotypic resistance was defined as a ≥ 5 -fold decrease in viral sensitivity *in vitro* from baseline. The clinical relevance of phenotypic and genotypic changes associated with ritonavir therapy has not been established.

Cross-resistance to other antiretrovirals

Among protease inhibitors variable cross-resistance has been recognized. Serial HIV isolates obtained from six patients during ritonavir therapy showed a decrease in ritonavir susceptibility *in vitro* but did not demonstrate a concordant decrease in susceptibility to saquinavir *in vitro* when compared to matched baseline isolates. However, isolates from two of these patients demonstrated decreased susceptibility to indinavir *in vitro* (8-fold). Isolates from 5 patients were also tested for cross-resistance to amprenavir and nelfinavir; isolates from 2 patients had a decrease in susceptibility to nelfinavir (12- to 14-fold), and none to amprenavir. Cross-resistance between ritonavir and reverse transcriptase inhibitors is unlikely because of the different enzyme targets involved. One ZDV-resistant HIV isolate tested *in vitro* retained full susceptibility to ritonavir.

TOXICOLOGY

The toxicology of ritonavir has been assessed in mice, rats, dogs and rabbits in studies ranging in duration from a single dose to six months of oral administration. All phases of the reproductive process have been evaluated for potential adverse effects, and a generally accepted battery of *in vitro* and *in vivo* mutagenicity studies has been conducted. The following section summarizes the findings from these studies. The most significant target organs in the toxicity studies have been the liver and retina. Retinal changes secondary to phospholipidosis were limited to rodents only and were considered not to pose any undue risk to humans. Dogs appeared to be less sensitive than the rodent to the hepatotoxic effects of ritonavir. Human clinical studies have not

disclosed a high incidence of hepatic complications (see **ADVERSE REACTIONS**).

Acute Toxicity

Ritonavir has a low order of acute toxicity in rodents by oral route but is more toxic when given intravenously. The difference is probably due to the fact that the acute toxicity produced by ritonavir is more related to plasma C_{max} than AUC values, and C_{max} is most likely considerably higher following intravenous injection. When given orally in a vehicle of propylene glycol and ethyl alcohol (95:5, v/v) containing two molar equivalents of p-toluene sulfonic acid monohydrate, the median lethal dose (LD_{50}) generally exceeds the limited dose of 2500 mg/kg for both mice and rats. Toxic signs for both species consisted of decreased activity, ataxia, dyspnea, squinting, prostration, and tremors.

When administered intravenously, the approximately lethal dose (ALD) ranged from 35 to 80 mg/kg for both species. Signs of toxicity included decreased activity, ataxia, dyspnea, exophthalmos, and clonic convulsions.

Sub-chronic Toxicity

Rat

A one-month rat study was conducted by gavage at 0, 15, 50, and 150/100 (male/ female) mg/kg/day. Drug exposure (AUC) values toward the end of the treatment period were 3.64, 27.61 and 63.32 mcg·h/mL for males and 5.34, 24.50 and 91.34 mcg·h/mL for females treated at 15, 50 and 150/100 mg/kg/day, respectively.

Treatment-related clinical signs of decreased activity, emaciation, hunched posture, weakness, and urine-staining of abdominal hair occurred in rats at the high dosages. Rats in the high dosage group also had lower mean body weights and body weight gains than the controls. Treatment-related differences from the controls in clinical pathology were limited to minimally increased serum globulin and monocystosis in rats treated at 50 mg/kg/day and higher. No changes in liver enzyme activities were noted. Mean liver weights were increased at 50 mg/kg/day and above and thyroid gland weights were increased in female rats at 100 mg/kg/day. Target organs were identified as the liver, thyroid, and eye. Changes in the liver consisted of hepatomegaly, multinucleated hepatocytes and/or mild focal periportal inflammation in rats at 50 mg/kg/day and higher. Mild to moderate hypertrophy of follicular epithelium also occurred in rats at 50 mg/kg/day and above.

Minimal hypertrophy and cytoplasmic granularity of the retinal pigment epithelium (RPE) were found in rats at the high dosage. Effects in the thyroid gland and the eye were reversible after a one-month recovery period, but the liver changes were not reversible following one-month of recovery. The no-toxic-effect level in this study was 15 mg/kg/day corresponding to a systemic exposure of 3.6 to 4.7 mcg·h/mL in male rats and 5.3 to 8.9 mcg·h/mL in female rats (approximately 1/25th of the expected human exposure of 150 mcg·h/mL from a dose of 600 mg

twice daily.

A three-month oral gavage study was conducted in rats at dosages of 0, 25, 75, and 175/125 (male/female) mg/kg/day. The mean AUC values toward the end of the treatment period were 18, 43, 97 mcg·h/mL for males and 21, 73 and 98 mcg·h/mL for females at corresponding dosages of 25, 75 and 175 (males) and 125 (females) mg/kg/day, respectively. Three male rats that received 175 mg/kg/day and two females given 125 mg/kg/day died during the treatment period. Ataxia, decreased activity, dehydration, emaciation, rough coat, hunched posture, weakness, tremors, cold to touch, pale and squinting eyes, urine-staining of abdominal hair, and discoloration of urine were noted in rats at the high dosage. Group mean body weights and food consumption for rats in the high-dosage group were significantly lower than the controls. At the preterminal eye examination, pale choroidal vasculature and dilated retinal vessels were seen in rats at the high dosage. Electroretinograms (ERGs) recorded near the end of the treatment period revealed decreases in mean values of A- and B-wave amplitudes and mean amplitude values for rod response along with a prolongation of the implicit times of the A-wave in the high dosage rats. The eye changes along with the effects on A- and B-wave amplitude values were still evident in rats that were held for a three-month recovery period. The mean values of erythrocytic parameters for the high dosage rats were significantly lower than the controls. The ALT and AST activities for the drug-treated rats were significantly increased over the controls. Increased mean GGT activities and cholesterol values were found for the mid and high dosage rats. The mean serum thyroid stimulating hormone (TSH) values for the drug-treated rats were higher than the controls, while the T₄ (thyroxine) values for the mid and high dosage males were lower than the controls. The liver weights of rats at all dosage levels were increased over the controls. Histopathologic evaluation revealed that the liver, eye, and stomach were major target organs. The hepatic changes (multinucleated hepatocytes, single cell necrosis, histiocytic microgranulomas, and chronic pericholangitis) were found in rats at all dosage levels, and the retinal alternations (hypertrophy of the RPE and retinal degeneration) were observed mainly in mid and high dosage rats. Minimal to mild pyloric gastritis and necrosis were noted in rats at mid and high dosages.

Ultrastructural evaluation of the eye revealed a considerable accumulation of phagosomes in the RPE of rats at mid and high dosages. Reduced or absent photoreceptor outer segments also occurred in rats at the high dosage. The liver from the drug-treated rats contained abundant irregular, dense-staining inclusions in both hepatocytes and phagocytic cells upon ultrastructural evaluation. The changes in the liver and eye were not reversible after three months of recovery. The no-toxic-effect level in this study was considered to be less than 25 mg/kg/day corresponding to a systemic exposure of 18 to 21 mcg·h/mL (approximately one-eighth of the expected human exposure of 150 mcg·h/mL from a dose of 600 mg twice daily).

A six month study was conducted in rats by oral gavage at dosages of 0, 25, 75, and 175/125 (male/female) mg/kg/day during Study Days 0 to 79. Thereafter, the high dosage levels for males and females were lowered to 150 and 100 mg/kg/day, respectively, due to excessive toxicity. The group mean AUC values on Study Day 174 were 14.3, 60.7 and 83.4 mcg·h/mL for males and 21.5, 76.2 and 174.5 mcg·h/mL for females at the corresponding dosages of 25, 75 and 150 (males)/100 (females) mg/kg/day. One mid dosage female, two high dosage males, and five

high dosage females died during the study. Dehydration, emaciation, hunched posture, decreased activity, weakness, sedation, tremors, cold to touch, matted hair, rough coat, squinting eyes, urine-staining of hair, salivation, and abnormal stool were noted in the high dosage rats. Group mean body weights and food consumption for rats in the high dosage group were lower than the controls. Pale choroidal vessels and/or dilated retinal vessels were seen in some of the high dosage rats at the preterminal eye examination. Significantly decreased hemoglobin and hematocrit values occurred in the mid and high dosage groups. RBC morphology changes suggested that a mild low grade hemolytic anemia occurred in individual rats. A mild to marked increase in serum ALT and AST values in some individual rats were seen at all dosage levels. Elevations of GGT, total bilirubin, ALP, and serum cholesterol values also occurred in the mid and high dosage rats. Mean serum triglyceride levels for male rats at all dosage levels were significantly decreased compared to the controls, while triglyceride values of the high dosage female rats were increased. The mean TSH values for the drug-treated rats were higher than the controls, and the T₄ (thyroxine) values for the mid and high dosage rats were lower than the controls. The mean liver weights in rats at all dosage levels were increased over the controls. Histopathology evaluations revealed that liver, eye, kidney, and thyroid were the major target organs. The changes in liver and eye were similar to those observed in the three-month rat studies. Treatment-related histologic changes in the kidney included mild to moderate, multifocal tubular degeneration occurring in rats in all dosage groups. Mild epithelial hypertrophy in the thyroid gland was noted in mid and high dosage rats. The reversibility of these changes was not assessed in this six-month study. The no-toxic-effect level in this study was less than 25 mg/kg/day corresponding to a systemic exposure of 14 to 22 mcg·h/mL which was approximately one-eighth of the expected human exposure of 150 mcg·h/mL from a dosage of 600 mg twice daily.

Dog

A one-month study in dogs was conducted by oral gavage at dosages of 0, 10, 50, and 200 mg/kg/day. No clear sex difference in mean plasma drug levels was apparent. The group mean AUC values for both males and females on Day 0 were 25.9, 75.2 and 160.7 mcg·h/mL and on Day 27 were 21.1, 17.1 and 240.3 mcg·h/mL at corresponding dosages of 10, 50 and 200 mg/kg/day, respectively. No deaths occurred during the course of treatment. Clinical signs were observed in dogs at 50 and 200 mg/kg/day and included emesis, increased salivation, diarrhea and/or abnormal stool. Dogs in the high dosage group also had incidences of dehydration, ataxia, decreased activity, and involuntary movements. Body weight loss was seen in some dogs at 200 mg/kg/day. Two female and one male high dosage dogs required supplemental feed to maintain their health. Treatment-related changes in clinical pathology were limited to mild increases in ALT, ALP, GGT, and bile acids in some high dosage dogs. Mean liver weights were significantly increased in dogs at the high dosage.

Target organs were identified as liver and thymus (liver hydropic degeneration and thymic atrophy) in dogs that received 200 mg/kg/day corresponding to a systemic exposure of 200 mcg·h/mL. Drug-related effects on the target organs were reversed during one-month of recovery. The no-toxic-effect level in this study was 50 mg/kg/day corresponding to a systemic exposure of 17.1 to 75.2 mcg·h/mL which was approximately one-third of the expected human

exposure of 150 mcg·h/mL from a dose of 600 mg twice daily.

A three-month study was conducted in dogs at dosages of 0, 10, 50, and 100 to 200 mg/kg/day. Dogs in the high dosage group received 200 mg/kg/day for 21 days, but due to excessive weight loss and morbidity, the dosage was reduced to 100 mg/kg/day in male dogs (Days 21 to 92) and suspended in female dogs. Treatment at 100 mg/kg/day was resumed after 13 days of recovery (Days 21 to 33) in the high dosage female dogs. The group mean AUC values on Study Day 82 were 25.1, 80.2 and 147.4 mcg·h/mL for males and 22.7, 50.5 and 22.3 mcg·h/mL for females at corresponding dosages of 10, 50 and 100 mg/kg/day, respectively. One high dosage female dog was euthanized on Day 86 in moribund condition. Decreased activity, emesis, excessive salivation, and diarrhea/abnormal stool were observed in mid and high dosage dogs. In female dogs that received 200 mg/kg/day, dehydration, emaciation, ataxia, weakness, tremors, hunched posture, and involuntary body movements were noted for Study Days 0 to 20. Body weight loss was evident in the high dosage dogs. Elevations of serum ALT, ALP, and GGT activities occurred in one male and four female dogs that received 200 mg/kg/day and achieving AUC values > 200 mcg·h/mL prior to the suspension of drug-treatment on Day 21. However, at the end of the treatment period no significant elevations in serum enzyme activity were found with the exception of a single high dosage female dog that was euthanized on Day 86. This dog had elevated ALP, ALT, GGT, and bile acids. The liver was a target organ, as evidenced by increased weight and histopathologic findings (pericholangitis, biliary hyperplasia, fibrosis, hydropic degeneration), in dogs that received 200/100 mg/kg/day and achieving AUC values > 200 mcg·h/mL on Study Day 14. However, none of the above changes were seen in dogs that were held for a two-month recovery period. The liver changes seen in the study appeared to be reversible. The no-toxic effect exposure (AUC) in this study was considered to be < 200 mcg·h/mL and the expected human exposure from a dose of 600 mg twice daily was 150 mcg·h/mL.

Ritonavir was administered by oral gavage to beagle dogs at dosages of 0, 10, 50 or 125 mg/kg/day for six months. The group mean AUC values on Study Day 152 were 18.3, 64.2 and 115.0 mcg·h/mL in males and 25.7, 133.6 and 204.6 mcg·h/mL in females at corresponding dosages of 10, 50 and 125 mg/kg/day, respectively. No deaths occurred during the study. Emesis, abnormal stool and/or diarrhea were observed in mid and high dosage dogs. Additional clinical signs seen in the high dosage dogs were decreased activity and a thin and/or emaciated appearance. Mean body weights and weight gains for the high dosage dogs were lower than the controls. Dietary supplementation was used for some high dosage dogs as a precaution against excessive weight loss and associated debilitation. Increases in serum ALP values were present in the mid and high dosage groups. Target organs were the liver and thymus. Liver changes included increased organ weights and hepatomegaly in the high dosage group. Diffuse hepatocellular hydropic degeneration was found in a single female in the high dosage group. This dog was found to have the highest individual plasma drug exposure (AUC=482 mcg·h/mL). Decreased thymic weights and thymic atrophy were apparent in the high dosage male dogs. The reversibility of changes seen in the liver and thymus was not assessed in this six-month study. The no-toxic-effect level in this study was considered to be 10 mg/kg/day corresponding to a systemic exposure of 18.3 to 25.7 mcg·h/mL which was approximately one-seventh of the expected human exposure of 150 mcg·h/mL. However, histopathological changes in liver were

only observed in a single female dog at the highest dosage (125 mg/kg/day) at a plasma drug exposure of 482 mcg·h/mL.

Special Studies

A three month dietary study was conducted in mice at dosages of 0, 200, 400, 600, and 1000 mg/kg/day to select dosages for the two-year carcinogenicity study. The group mean AUC values in males were 57.1, 130.7, 219.1 and 381.4 mcg·h/mL and in females were 112.0, 209.1, 320.4 and 396.7 mcg·h/mL at the corresponding dosages of 200, 400, 600 and 1000 mg/kg/day.

No drug-related deaths were observed, but hunched posturing, alopecia and urine-stained or matted hair were noted at dosages of 600 mg/kg/day and above. Mean body weights of mice at 600 mg/kg/day and above were significantly decreased from controls. Differences from controls in clinical chemistry parameters included increased AST, ALT, cholesterol, and triglycerides in drug-treated mice. Increases in ALP, GGT, and total protein were noted in mice receiving 400 mg/kg/day and above. Mean liver weights were increased in all drug-treated mice. Pathology in the liver consisted of hepatocytomegaly, hepatocyte necrosis, and histiocytic microgranulomas in all drug-treated mice, vacuolation and increased mitosis in hepatocytes of mice receiving 400 mg/kg/day and higher doses. Treatment-related pathology of the eye consisted of hypertrophy of RPE in mice at 400 mg/kg/day or higher.

A three-month dietary study was conducted in rats at dosages of 0, 50, 100, 160, and 200 mg/kg/day and 0, 30, 75, 125, and 175 mg/kg/day for males and females, respectively to select dosages for the two-year carcinogenicity study. The group mean AUC values toward the end of the treatment period were 6.23, 21.72, 57.32 and 93.18 mcg·h/mL for males and 1.62, 23.41, 67.05 and 105.35 mcg·h/mL for females at corresponding nominal dosages of 50, 100, 160 and 200 mg/kg/day for males and 30, 75, 125 and 175 mg/kg/day for females. There were no drug-related deaths in the study. Emaciation, rough coat and hunched posture were noted in the high dosage rats.

Group mean body weights and food consumption for rats at the two higher dosage groups were lower than the controls. The mean ALT and AST activities for the drug-treated rats at all dosage levels were increased over the controls. Significantly increased GGT activities were noted in rats at the two higher dosage groups. Mean serum cholesterol values for rats at the three top dosage levels were higher than the controls. The mean serum thyroxine (T₄) values for the drug-treated rats were lower than the controls, while the mean TSH values for female rats at the two top dosages were greater than the controls. The mean liver weights for rats at the top three dosage levels were increased over the controls. Histopathologic evaluation revealed the liver, eye and thyroid were major target organs. The hepatic and retinal changes seen in this dietary study were similar to those noted in the three-month oral gavage study in rats. The liver changes were noted at all dosage levels, while the ocular alterations were limited to rats at the two top dosage levels. Thyroid follicular epithelial cell hypertrophy occurred in rats at the three top dosage levels.

Ritonavir was evaluated for the potential to produce delayed contact hypersensitivity in guinea pigs. The Maximization Method was used in this study and the data generated indicated that ritonavir did not induce delayed contact hypersensitivity in guinea pigs.

Fertility and General Reproductive Performance

Rats

Ritonavir was administered orally by gavage to female rats at dosages of 0, 20, 40, and 75 mg/kg/day beginning at 14 days prior to mating with males that were treated at dosages of 0, 20, 40, and 125 mg/kg/day beginning at 28 days prior to mating. The treatment in female rats was continued through mating until gestation Day 9. The group mean plasma AUC values for males near the end of the pre-mating period were 8.2, 19.7 and 61.0 mcg·h/mL, respectively, for the 20, 40, and 125 mg/kg/day treatment groups. The corresponding values for females were 14.6, 33.1 and 90.5 mcg·h/mL, respectively, for the 20, 40 and 75 mg/kg/day treatment groups. There were no treatment-related deaths in the study. Maternal toxicity consisted of adverse clinical signs and decreases in mean body weights and food intake in the mid and high dosage groups.

There were no treatment-related effects on the estrous cycle or male and female reproductive indices. Maternal survival and pregnancy status of the ritonavir-treated groups were also comparable to the controls. No treatment-related effects were seen in the number of corpora lutea, implantation sites, viable and nonviable embryos. There were no increases in the incidence of preimplantation and postimplantation losses. The no-toxic-effect level for systemic toxicity in F₀ generation rats was 20 mg/kg/day. However, there were no adverse effects on male or female reproduction or early embryonic development up to the highest dosage (125/75 mg/kg/day) tested.

Developmental Toxicity

Rats

Ritonavir was administered orally to mated female rats at dosages of 0, 15, 35, and 75 mg/kg/day from Gestation Day 6 to 17. Three high dosage rats were euthanized in moribund condition during the study. The group mean plasma AUC values on Gestation Day 16 were 17.3, 34.3 and 45.2 mcg·h/mL at dosages of 15, 35 and 75 mg/kg/day, respectively. Decreased activity, emaciation, dehydration, rough coat and/or matted coat, hunched posture, tremors, and noisy respiration were observed in rats at the high dosage level. Marked decreases in body weights and food consumption were evident in the high dosage group. Reduction in food consumption accompanied by a reduction in body weight gain was also noted for the mid dosage group during Gestation Days 6 to 9. No effects were found in the number of corpora lutes or implantation sites. Developmental toxicity in the high dosage group was characterized by increased postimplantation loss, decreased fetal body weights, and an increased incidence of ossification delays and developmental variations (enlarged fontanelles, cryptorchidism and wavy ribs). Developmental toxicity at the 35 mg/kg/day dosage level was characterized by a slight increase in cryptorchidism. No treatment-related malformations were observed in this study.

Developmental toxicity occurred only at maternally toxic dosages. The no-effect level for maternal and developmental toxicity was 15 mg/kg/day corresponding to a systemic exposure of 17.3 mcg·h/mL.

Rabbits

Ritonavir was administered to mated female rabbits by oral gavage at dosages of 0, 25, 50, and 110 mg/kg/day from Gestation Day 6 to 19. The group mean plasma AUC values on Gestation Day 20 were 1.30 and 28.55 mcg·h/mL at dosages of 25 and 50 mg/kg/day, respectively. Plasma AUC values were not calculated for the 110 mg/kg/day group because plasma samples were obtained from the three surviving rabbits at only two time points. Four deaths in rabbits given 110 mg/kg/day were considered to be possibly drug-related. There was an increased incidence of decreased defecation and soft stool in all drug-treated groups. The observation of no stool was noted in mid and high dosage groups; rales and mucoid stool occurred only at the high dosage. Marked decreases in body weights, body weight gain and food consumption were noted in the high dosage group. Developmental toxicity was evident at the high dosage level with four whole litter resorptions and in surviving litters a significant increase in postimplantation losses, decreased litter size and decreased uterine and fetal weights. There were no drug-related fetal malformations in this study.

The no-observable-effect level was 50 mg/kg/day with respect to maternal and developmental toxicity.

Peri-/Postnatal Toxicity

Rats

Mated female rats were administered ritonavir orally at dosages of 0, 15, 35, or 60 mg/kg/day beginning on Gestation Day (GD) 6. Treatment continued throughout gestation, parturition and lactation; the final dosage was given on Postpartum Day (PD) 20. Plasma drug levels were not determined in this study. No deaths or treatment-related clinical signs were observed among the F₀ dams. Dams in the 60 mg/kg/day group gained less weight and consumed less food during GD 6 to 9. Gestation length, litter size at birth, and F₁ pup growth and survival were unaffected. No effects on the time of appearance of developmental landmarks or learning as measured by a passive avoidance test were evident. The ontogeny of various reflexes were unaffected. The reproductive competence of the F₁ generation was unaffected. Therefore, the no-observed-effect level for developmental toxicity was considered to be 60 mg/kg/day, the highest dosage tested.

Carcinogenicity

Carcinogenicity studies with ritonavir have been conducted in mice and rats. In male mice, at dosage levels of 50, 100, or 200 mg/kg/day, there was a dose dependent increase in the incidence of both adenomas and combined adenomas and carcinomas in the liver. Based on the drug exposure (AUC) measurements, the exposure at the high dosage was approximately 0.3-fold for males that of exposure in humans with the recommended therapeutic dose (600 mg twice daily).

There were no carcinogenic effects seen in females at the dosages tested. The exposure at the high dosage was approximately 0.6-fold for the females that of the exposure in humans. In rats dosed at levels of 7, 15, or 30 mg/kg/day there were no carcinogenic effects. In this study the exposure at the high dose was approximately 5% that of the exposure in humans with the 600 mg twice daily regimen. Based on the exposures achieved in the animal studies, the significance of the observed effects is not known.

Mutagenicity

Ritonavir was not found to be mutagenic or clastogenic in a battery of *in vitro* and *in vivo* assays including the Ames bacterial reverse mutation assay using *S. Typhimurium* and *E. coli*, the mouse lymphoma assay, the mouse micronucleus test and chromosomal aberration assays in human lymphocytes.

REFERENCES

1. Bugelski PJ, Kirsh R, Hart TK. HIV protease inhibitors: effects on viral maturation and physiologic function in macrophages. *J Leukoc Biol* 1994; 56:374-380.
2. Caliendo AM, Hirsch MS. Combination therapy for infection due to human immunodeficiency virus type 1. *Clin Infect Dis* 1994; 18:516-524.
3. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. *Lancet* 1998; 351:543-49.
4. Coffin JM. HIV population dynamics *in vivo*: implications for genetic variation, pathogenesis, and therapy. *Sci* 1995; 267:483-489.
5. Church JA. Clinical aspects of HIV infection. *Pediatric Ann.* 1993;22(7):417-427.
6. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. *N Eng J Med* 1995; 333:1528-1533.
7. Darke PL, Huff JR. HIV protease as an inhibitor target for the treatment of AIDS. *Adv Pharmacol* 1994; 25:399-455.
8. Hammer SM, Kessler HA, Saag MS. Issues in combination antiretroviral therapy: a review. *J Acq Immun Def Synd* 1994; 7(Suppl. 2):524-537.
9. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD₄ lymphocytes in HIV-1 infection. *Nature* 1995; 373:123-126.
10. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. *Clin Pharmacokinet* 1998 Oct;35(4):275-91. Review. Erratum in: *Clin Pharmacokinet* 1998 Dec;35(6):473.
11. Hsu A, Granneman R, Rynkiewicz K, et al. Kinetics of ABT-538, a protease inhibitor, in human after single oral rising doses. *Pharm Res* 1994; 11(Suppl):S400.
12. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has a high oral bioavailability. *Proc Natl Acad Sci* 1995; 92:2484-2488.
13. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. *Proc Natl Acad Sci USA* 1988; 85:4686-4690.
14. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease to treat HIV-1 infection. *N Eng J Med* 1995; 333:1534-1539.

15. Mathez D, Bagnarelli P, Gorin I, et al. Reductions in viral load and increases in T lymphocyte numbers in treatment-naïve patients with advanced HIV-1 infection treated with zidovudine, zalcitabine and zalcitabine triple therapy. *Antiviral Therapy* 1997;2(3):175-83.
16. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. *Ann Intern Med* 1995; 122:573-579.
17. Mitsuya H, Yarchoan R, Kageyama S, Broder S. Targeted therapy of human immunodeficiency virus-related disease. *FASEB J* 1991; 5:2369-2381.
18. Roberts NA, Craig JC, Duncan IB. HIV protease inhibitors. *Biochem Soc Trans* 1992; 20:513-516.
19. Tudor-Williams G, St. Clair MH, McKinney RE et al. HIV-1 Sensitivity to zidovudine and clinical outcome in children. *Lancet*. 1992;339(8784):15-19.
20. Wei X, Ghosh SK, Tayler ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. *Nature* 1995; 373:117-122.
21. Whitcup SM, Butler KM, Caruso R et al. Retinal toxicity in human immunodeficiency virus-infected children treated with 2,3'-dideoxyinosine. *Am J Ophthalmol*. 1992;113(1):1-7.

PART III: CONSUMER INFORMATION

Pr NORVIR® ritonavir oral solution

This leaflet is part III of a three-part "Product Monograph" published when NORVIR® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about NORVIR®. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

NORVIR® is for adults and children 2 years of age or older who are infected with the human immunodeficiency virus (HIV), the virus which causes AIDS.

NORVIR® is prescribed for use in combination with other antiretroviral medicines.

What it does:

NORVIR® is an inhibitor of the HIV protease enzyme. It helps control HIV infection by inhibiting or interfering with the protease enzyme that HIV needs to multiply.

NORVIR® is not a cure for HIV infection or AIDS. People taking NORVIR® may still develop infections or other serious illnesses associated with HIV disease and AIDS.

When it should not be used:

NORVIR® should not be taken if you/your child:

- are allergic to ritonavir or to any of the nonmedicinal ingredients in NORVIR®. (Refer to the subheading "**What the nonmedicinal ingredients are**" for a complete listing)
- are currently taking any of the following medicines:
 - Xatral® (alfuzosin) - used to treat high blood pressure;
 - Cordarone® (amiodarone), Tambocor® (flecainide), Vascor® (bepidil)**, Rythmol® (propafenone), quinidine - used to treat irregular heart beats;
 - Hismanal® (astemizole)* or Seldane® (terfenadine)* - antihistamines
 - Orap® (pimozide) - used to treat schizophrenia;
 - Propulsid® (cisapride)* - used to relieve certain stomach problems;
 - ergotamine, dihydroergotamine, ergonovine, methylegonovine (used to treat headaches), such as Cafegot®, Migranal®, D.H.E. 45®, Ergotrate Maleate, Methergine, and others;
 - Vfend® (voriconazole) – antifungal;
 - Mevacor® (lovastatin) or Zocor® (simvastatin) – used to lower blood cholesterol;
 - Halcion® (triazolam) – used to relieve anxiety and/or trouble sleeping;

- Versed® (midazolam).

* Products no longer marketed in Canada.

**Product not available in Canada.

- are taking both rifampin and saquinavir. NORVIR® should not be taken with rifampin and saquinavir. Rifampin is also known as Rimactane®, Rifadin®, Rifater®, or Rifamate®; saquinavir is also known as Invirase®.
- are taking products containing St. John's Wort (*Hypericum perforatum*) as this may stop NORVIR® from working properly.
- are currently taking any of these medications, your doctor may switch your medication.

What the medicinal ingredient is:

ritonavir

What the important nonmedicinal ingredients are:

NORVIR® oral solution also contains ethanol, water, polyoxyl 35 castor oil, propylene glycol, anhydrous citric acid to adjust pH, saccharin sodium, peppermint oil, creamy caramel flavoring, and FD&C Yellow No. 6.

What dosage forms it comes in:

This medicine comes in:

- Oral solution (NORVIR® 80 mg/mL)
- Soft elastic capsules (NORVIR® SEC 100 mg)

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Tell your doctor if you or your child develop symptoms such as nausea, vomiting and abdominal pain. These may be signs of problems with your pancreas (pancreatitis). Your doctor must decide if these are related to pancreatitis and what to do about them.

BEFORE using NORVIR® talk to your doctor or pharmacist if:

- you/your child have liver problems or are infected with Hepatitis B or Hepatitis C.
- you/your child have diabetes, or symptoms such as frequent urination, and/or increase in thirst.
- you/your child have hemophilia: Patients taking NORVIR® may have increased bleeding.
- you/your child are taking or planning to take other medicines, including prescription, herbal and other medicines you can buy without a prescription.
- you have heart disease or heart condition.
- you are pregnant or breast-feeding: Pregnant or breast-feeding mothers should not take NORVIR® unless specifically directed by the doctor. Be sure to tell your doctor

immediately if you are or may be pregnant or if you are breast-feeding a baby. It is recommended that HIV-infected women should not breast-feed their infants because of the possibility your baby can be infected with HIV through your breast milk.

NORVIR[®] does not reduce the risk of passing HIV to others with sexual contact or blood contamination. You should use appropriate precautions, such as practicing safe sex, and not reusing or sharing needles.

Changes in body fat have been seen in some patients taking antiretroviral therapy (see **SIDE EFFECTS AND WHAT TO DO ABOUT THEM**).

INTERACTIONS WITH THIS MEDICATION

Drugs that may interact with NORVIR[®] include:

NORVIR[®] may interact with certain other medications with possible clinical effects. The use of the following medicines together with NORVIR[®] should only take place on the basis of medical advice:

- medicines used to treat erectile dysfunction: [*e.g.*, Viagra[®] (sildenafil), or Cialis[®] (tadalafil)]. Levitra[®] (vardenafil) should not be taken with NORVIR[®];
- medicines used to lower blood cholesterol [*e.g.*, Lipitor[®] (atorvastatin), Crestor[®] (rosuvastatin)];
- some medicines affecting the immune system [*e.g.*, cyclosporin, Rapamune[®] (sirolimus), tacrolimus];
- some medicines used to treat seasonal allergies and ear and eye infections [*e.g.*, Decadron[®] (dexamethasone), Flonase[®] (fluticasone propionate), prednisone];
- medicines used to treat AIDS and related infections [*e.g.*, Agenerase[®] (amprenavir), Crixivan[®] (indinavir), Viracept[®] (nelfinavir), Invirase[®] (saquinavir), Videx[®] (didanosine), Mycobutin[®] (rifabutin), Aptivus[®] (tipranavir), Rescriptor[®] (delavirdine), Reyataz[®] (atazanavir), Celsentri[®] (maraviroc), Telzir[®] (fosamprenavir), Prezista[®] (darunavir)];
- medicines used to treat depression [*e.g.*, Serzone[®] (trazodone), desipramine, bupropion];
- certain heart medicines such as calcium channel antagonists (*e.g.*, Tiazac[®] (diltiazem), Adalat[®] (nifedipine), Isoptin[®] (verapamil));
- medicines used to correct heart rhythm [*e.g.*, systemic lidocaine, digoxin];
- antifungals [*e.g.*, Nizoral[®] (ketoconazole), Sporanox[®] (itraconazole)];
- morphine-like medicines [*e.g.*, methadone; Demerol[®] (meperidine)];
- anticonvulsants [*e.g.*, Tegretol[®] (carbamazepine), Dilantin[®] (phenytoin), phenobarbital];
- warfarin;
- certain antibiotics [*e.g.*, Mycobutin[®] (rifabutin), Biaxin[®] (clarithromycin)];
- rifampin, also known as Rimactane[®], Rifadin[®], Rifater[®], or Rifamate[®];

- theophylline.
- medicines used to treat cancer (vincristine, vinblastine)

If you are taking oral contraceptives (“the pill”) or the contraceptive patch (*i.e.*, ethinyl estradiol) to prevent pregnancy, you should use a different type of contraception since NORVIR[®] may reduce the effectiveness of oral or patch contraceptives.

NORVIR[®] Oral Solution contains alcohol. Talk with your/your child’s doctor if you/your child are taking or planning to take Flagyl[®] (metronidazole) or Antabuse[®] (disulfiram). Severe nausea and vomiting can occur.

PROPER USE OF THIS MEDICATION

It is important that you/your child take NORVIR[®] every day exactly as your doctor prescribed it. Even if you/your child feel better, do not stop taking NORVIR[®] without talking to your doctor. Using NORVIR[®] as recommended should give you the best chance to delay the development of resistance to the product.

It is therefore important that you remain under the supervision of your doctor while taking NORVIR[®].

Usual dose:

The usual dose for adults is 7.5 mL of the oral solution twice a day (morning and night), in combination with other anti-HIV medicines.

The dose for children over 2 years of age will be determined by your doctor based on the child’s height and weight.

Take NORVIR[®] with food to help it work better.

After use, clean the dosage cup immediately with hot water and dish soap and dry. The dosage cup **must** be dry before use.

Overdose:

If you/your child realize you have taken more NORVIR[®] than you were supposed to, contact your doctor or local poison centre right away. If you cannot reach your/your child’s doctor, go to the hospital. NORVIR[®] Oral Solution contains 43% alcohol and accidental ingestion could be toxic and potentially lethal to a young child.

Missed Dose:

If you/your child miss a dose of NORVIR[®], it should be taken as soon as possible, and the next scheduled dose taken at its regular time. If it is almost time for your/your child’s next dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not double the next dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

The most commonly reported side effects of NORVIR® are abdominal pain, diarrhea, feeling weak or tired, headache, nausea, vomiting, changes in taste, loss of appetite, dizziness, tingling feeling or numbness in hands, feet or around the lips and rash.

- If you/your child have liver disease such as Hepatitis B and Hepatitis C, taking NORVIR® may worsen your liver disease.
- Some patients taking NORVIR® can develop serious problems with their pancreas (pancreatitis) which may cause death. Tell your doctor if you have nausea, vomiting, or abdominal pain. These may be signs of pancreatitis.
- Some patients have large increases in triglycerides and cholesterol (forms of fat that are found in your blood).
- Diabetes and high blood sugar (hyperglycemia) may occur in patients taking protease inhibitors such as NORVIR®. Symptoms of diabetes or high blood sugar may include frequent urination or increased thirst. Let your doctor know if you have or develop these symptoms while taking NORVIR®.
- Some patients with hemophilia have increased bleeding with protease inhibitors.
- Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breasts, and around the trunk. Loss of fat from the legs, arms and face may also happen. The cause and long-term health effects of these conditions are not known at this time.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
Common	Diarrhea	✓		
	Rash	✓		
	Headache	✓		
	Nausea	✓		
	Vomiting	✓		
	Tingling feeling in hands, feet and around lips	✓		
Uncommon	Chest Pain		✓	
	Pancreatitis		✓	
	- Abdominal Pain		✓	
	- Nausea		✓	
	- Vomiting		✓	

This is not a complete list of side effects. For any unexpected effects while taking NORVIR®, contact your doctor or pharmacist.

HOW TO STORE IT

Keep NORVIR® and all other medicines out of the reach of children.

NORVIR® oral solution should be stored at room temperature, between 20°C-25°C. **DO NOT REFRIGERATE. SHAKE WELL BEFORE EACH USE.** Avoid exposure to excessive heat. Keep cap tightly closed.

It is important to keep NORVIR® in the original package. Do not transfer to any other container.

Do not use after the expiry date stated on the pack.

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected side effects of drugs. If you suspect you have had serious or unexpected reaction to this drug you may notify Canada Vigilance:

By toll-free telephone: 866-234-2345
 By toll-free fax: 866-678-6789
 Online: www.healthcanada.gc.ca/medeffect
 By email: CanadaVigilance@hc-sc.gc.ca

By regular mail:
 Canada Vigilance National Office
 Marketed Health Products Safety and Effectiveness Information Bureau
 Marketed Health Products Directorate
 Health Products and Food Branch
 Health Canada
 Tunney’s Pasture, AL 0701C
 Ottawa ON K1A 0K9

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:
<http://www.abbott.ca>
 or by contacting the sponsor, Abbott Laboratories Limited, at:
 1-800-699-9948.

This leaflet was prepared by Abbott Laboratories, Limited, St. Laurent, Qc. H4S 1Z1

Last revised: June 5, 2008

PART III: CONSUMER INFORMATION
PrNORVIR® SEC
ritonavir soft elastic capsules

This leaflet is part III of a three-part "Product Monograph" published when NORVIR® SEC was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about NORVIR® SEC. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

NORVIR® SEC is for adults and children 2 years of age or older who are infected with the human immunodeficiency virus (HIV), the virus which causes AIDS.

NORVIR® SEC is prescribed for use in combination with other antiretroviral medicines.

What it does:

NORVIR® SEC is an inhibitor of the HIV protease enzyme. It helps control HIV infection by inhibiting or interfering with the protease enzyme that HIV needs to multiply.

NORVIR® SEC is not a cure for HIV infection or AIDS. People taking NORVIR® SEC may still develop infections or other serious illnesses associated with HIV disease and AIDS.

When it should not be used:

Do not take NORVIR® SEC if you/your child:

- are allergic to ritonavir or to any of the nonmedicinal ingredients in NORVIR® SEC. (Refer to the subheading "**What the nonmedicinal ingredients are**" for a complete listing)
- are currently taking any of the following medicines:
 - Xatral® (alfuzosin) - used to treat high blood pressure;
 - Cordarone® (amiodarone), Tambocor® (flecainide), Vascor® (bepiridil)**, Rythmol® (propafenone), quinidine - used to treat irregular heart beats;
 - Hismanal® (astemizole)* or Seldane® (terfenadine)* - antihistamines
 - Orap® (pimozide) - used to treat schizophrenia;
 - Propulsid® (cisapride)* - used to relieve certain stomach problems;
 - ergotamine, dihydroergotamine, ergonovine, methylegonovine (used to treat headaches), such as Cafergot®, Migranal®, D.H.E. 45®, Ergotrate Maleate, Methergine, and others;
 - Vfend® (voriconazole) – antifungal;
 - Mevacor® (lovastatin) or Zocor® (simvastatin) – used to lower blood cholesterol;
 - Halcion® (triazolam) – used to relieve anxiety and/or trouble sleeping;

- Versed® (midazolam).

* Products no longer marketed in Canada.

**Product not available in Canada.

- are taking both rifampin and saquinavir. NORVIR® SEC should not be taken with rifampin and saquinavir. Rifampin is also known as Rimactane®, Rifadin®, Rifater®, or Rifamate®; saquinavir is also known as Invirase®.
- are taking products containing St. John's Wort (*Hypericum perforatum*) as this may stop NORVIR® SEC from working properly.
- are currently taking any of these medications, your doctor may switch your medication.

What the medicinal ingredient is:

ritonavir

What the important nonmedicinal ingredients are:

NORVIR® SEC capsules also contain butylated hydroxytoluene, ethanol, gelatin, black opacode ink (iron oxide), oleic acid, polyoxyl 35 castor oil, purified water, titanium dioxide, sorbitol and glycerin.

What dosage forms it comes in:

This medicine comes in:

- Oral solution (NORVIR® 80 mg/mL)
- Soft elastic capsules (NORVIR® SEC 100 mg)

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Tell your doctor if you or your child develop symptoms such as nausea, vomiting and abdominal pain. These may be signs of problems with your pancreas (pancreatitis). Your doctor must decide if these are related to pancreatitis and what to do about them.

BEFORE using NORVIR® SEC talk to your doctor or pharmacist if:

- you/your child have liver problems or are infected with Hepatitis B or Hepatitis C.
- you/your child have diabetes, or symptoms such as frequent urination, and/or increase in thirst.
- you/your child have hemophilia: Patients taking NORVIR® SEC may have increased bleeding.
- you/your child are taking or planning to take other medicines, including prescription, herbal and other medicines you can buy without a prescription.
- you have heart disease or heart condition.
- you are pregnant or breast-feeding: Pregnant or breast-feeding mothers should not take NORVIR® SEC unless specifically directed by the doctor. Be sure to tell your doctor

immediately if you are or may be pregnant or if you are breast-feeding a baby. It is recommended that HIV-infected women should not breast-feed their infants because of the possibility your baby can be infected with HIV through your breast milk.

NORVIR[®] SEC does not reduce the risk of passing HIV to others with sexual contact or blood contamination. You should use appropriate precautions, such as practicing safe sex, and not reusing or sharing needles.

Changes in body fat have been seen in some patients taking antiretroviral therapy (see **SIDE EFFECTS AND WHAT TO DO ABOUT THEM**).

INTERACTIONS WITH THIS MEDICATION

Drugs that may interact with NORVIR[®] SEC include:

NORVIR[®] may interact with certain other medications with possible clinical effects. The use of the following medicines together with NORVIR[®] should only take place on the basis of medical advice:

- medicines used to treat erectile dysfunction: [e.g., Viagra[®] (sildenafil), or Cialis[®] (tadalafil)]. Levitra[®] (vardenafil) should not be taken with NORVIR[®];
- medicines used to lower blood cholesterol [e.g., Lipitor[®] (atorvastatin), Crestor[®] (rosuvastatin)];
- some medicines affecting the immune system [e.g., cyclosporin, Rapamune[®] (sirolimus), tacrolimus];
- some medicines used to treat seasonal allergies and ear and eye infections [e.g., Decadron[®] (dexamethasone), Flonase[®] (fluticasone propionate), prednisone];
- medicines used to treat AIDS and related infections [e.g., Agenerase[®] (amprenavir), Crixivan[®] (indinavir), Viracept[®] (nelfinavir), Invirase[®] (saquinavir), Videx[®] (didanosine), Mycobutin[®] (rifabutin), Aptivus[®] (tipranavir), Rescriptor[®] (delavirdine) Reyataz[®] (atazanavir), Celsentri[®] (maraviroc), Telzir[®] (fosamprenavir), Prezista[®] (darunavir)];
- medicines used to treat depression [e.g., Serzone[®] (trazodone), desipramine, bupropion];
- certain heart medicines such as calcium channel antagonists (e.g., Tiazac[®] (diltiazem), Adalat[®] (nifedipine), Isoptin[®] (verapamil));
- medicines used to correct heart rhythm [e.g., systemic lidocaine, digoxin];
- antifungals [e.g., Nizoral[®] (ketoconazole), Sporanox[®] (itraconazole)];
- morphine-like medicines [e.g., methadone; Demerol[®] (meperidine)];
- anticonvulsants [e.g., Tegretol[®] (carbamazepine), Dilantin[®] (phenytoin), phenobarbital];
- warfarin;
- certain antibiotics [e.g., Mycobutin[®] (rifabutin), Biaxin[®] (clarithromycin)];
- rifampin, also known as Rimactane[®], Rifadin[®], Rifater[®], or Rifamate[®];

- theophylline.
- medicines used to treat cancer (vincristine, vinblastine)

If you are taking oral contraceptives (“the pill”) or the contraceptive patch (*i.e.*, ethinyl estradiol) to prevent pregnancy, you should use a different type of contraception since NORVIR[®] may reduce the effectiveness of oral or patch contraceptives.

PROPER USE OF THIS MEDICATION

It is important that you/your child take NORVIR[®] SEC every day exactly as your doctor prescribed it. Even if you/your child, do not stop taking NORVIR[®] SEC without talking to your doctor. Using NORVIR[®] SEC as recommended should give you the best chance to delay the development of resistance to the product.

It is therefore important that you remain under the supervision of your doctor while taking NORVIR[®] SEC.

Usual dose:

The usual dose for adults is 600 mg (6 capsules) twice daily, in combination with other anti-HIV medicines.

The dose for children over 2 years of age will be determined by your doctor based on the child’s height and weight.

Take NORVIR[®] SEC with food to help it work better.

Overdose:

If you/your child realize you have taken more NORVIR[®] SEC than you were supposed to, contact your doctor or local poison control centre right away. If you cannot reach your/your child’s doctor, go to the hospital.

Missed Dose:

If you/your child miss a dose of NORVIR[®] SEC, it should be taken as soon as possible, and the next scheduled dose taken at its regular time. If it is almost time for your/your child’s next dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not double the next dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

The most commonly reported side effects of NORVIR[®] are abdominal pain, diarrhea, feeling weak or tired, headache, nausea, vomiting, changes in taste, loss of appetite, dizziness, tingling feeling or numbness in hands, feet or around the lips and rash.

- If you/your child have liver disease such as Hepatitis B and Hepatitis C, taking NORVIR[®] SEC may worsen your liver disease.
- Some patients taking NORVIR[®] SEC can develop serious problems with their pancreas (pancreatitis) which may cause death. Tell your doctor if you have nausea, vomiting, or abdominal pain. These may be signs of pancreatitis.
- Some patients have large increases in triglycerides and cholesterol (forms of fat that are found in your blood).

- Diabetes and high blood sugar (hyperglycemia) may occur in patients taking protease inhibitors such as NORVIR® SEC. Symptoms of diabetes or high blood sugar may include frequent urination or increased thirst. Let your doctor know if you have or develop these symptoms while taking NORVIR® SEC.
- Some patients with hemophilia have increased bleeding with protease inhibitors.
- Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck (“buffalo hump”), breasts, and around the trunk. Loss of fat from the legs, arms and face may also happen. The cause and long-term health effects of these conditions are not known at this time.

not transfer to any other container.
Do not use after the expiry date stated on the pack.

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected side effects of drugs. If you suspect you have had serious or unexpected reaction to this drug you may notify Canada Vigilance:

By toll-free telephone: 866-234-2345
By toll-free fax: 866-678-6789
Online: www.healthcanada.gc.ca/medeffect
By email: CanadaVigilance@hc-sc.gc.ca

By regular mail:
Canada Vigilance National Office
Marketed Health Products Safety and Effectiveness Information Bureau
Marketed Health Products Directorate
Health Products and Food Branch
Health Canada
Tunney’s Pasture, AL 0701C
Ottawa ON K1A 0K9

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom / effect		Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
		Only if severe	In all cases	
Common	Diarrhea	✓		
	Rash	✓		
	Headache	✓		
	Nausea	✓		
	Vomiting	✓		
	Tingling feeling in hands, feet and around lips	✓		
Uncommon	Chest Pain		✓	
	Pancreatitis		✓	
	- Abdominal Pain		✓	
	- Nausea		✓	
	- Vomiting		✓	

This is not a complete list of side effects. For any unexpected effects while taking NORVIR® SEC, contact your doctor or pharmacist.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:
<http://www.abbott.ca>
or by contacting the sponsor, Abbott Laboratories Limited, at:
1-800-699-9948.

This leaflet was prepared by Abbott Laboratories, Limited, St. Laurent, Qc. H4S 1Z1

Last revised: June 5, 2008

HOW TO STORE IT

Keep NORVIR® SEC and all other medicines out of the reach of children.

NORVIR® SEC soft gel capsules should be stored between 2°C-8°C in a refrigerator. If you keep NORVIR® SEC outside of the refrigerator, do not store above 25°C and discard any unused contents after 30 days. Avoid exposure to excessive heat. Protect from light.

It is important to keep NORVIR® SEC in the original package. Do